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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13355/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated
ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information
on the best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related
targets. It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data
presented in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR
classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent,
citable, point-in-time record that will survive database updates.
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Overview: The majority of biological solutes are charged
organic or inorganic molecules. Cellular membranes are
hydrophobic and, therefore, effective barriers to separate them
allowing the formation of gradients, which can be exploited, for
example, in the generation of energy. Membrane transporters
carry solutes across cell membranes, which would otherwise be
impermeable to them. The energy required for active transport
processes is obtained from ATP turnover or by exploiting ion
gradients.
ATP-driven transporters can be divided into three major classes:
P-type ATPases; F-type or V-type ATPases and ATP-binding
cassette transporters. The first of these, P-type ATPases, are
multimeric proteins, which transport (primarily) inorganic
cations. The second, F-type or V-type ATPases, are
proton-coupled motors, which can function either as
transporters or as motors. Last, are ATP-binding cassette
transporters, heavily involved in drug disposition as well as
transporting endogenous solutes.
The second largest family of membraine proteins in the human
genome, after the G protein-coupled receptors, are the SLC solute
carrier family. Within the solute carrier family, there are not only
a great variety of solutes transported, from simple inorganic ions
to amino acids and sugars to relatively complex organic
molecules like haem. The solute carrier family includes 52
families of almost 400 members. Many of these overlap in terms
of the solutes that they carry. For example, amino acids
accumulation is mediated by members of the SLC1, SLC3/7,
SLC6, SLC15, SLC16, SLC17, SLC32, SLC36, SLC38 and SLC43
families. Further members of the SLC superfamily regulate ion
fluxes at the plasma membrane, or solute transport into and out
of cellular organelles. Some SLC family members remain orpahn
transporters, in as much as a physiological function has yet to be
dtermined. Within the SLC superfamily, there is an abundance
in diversity of structure. Two families (SLC3 and SLC7) only
generate functional transporters as heteromeric partners, where
one partner is a single TM domain protein. Membrane topology
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predictions for other families suggest 3,4,6,7,8,9,10,11,12,13 or
14 TM domains. The SLC transporters include members which
function as antiports, where solute movement in one direction is
balanced by a solute moving in the reverse direction. Symports
allow concentration gradients of one solute to allow movement
of a second solute across a membrane. A third, relatively small
group are equilibrative transporters, which allow solutes to travel
across membranes down their concentration gradients. A more
complex family of transporters, the SLC27 fatty acid transporters
also express enzymatic function. Many of the transporters also
express electrogenic properties of ion channels.
Family structure
This is a complete listing of transporter families included in the online IUPHAR/BPS Guide to PHARMACOLOGY database. Summary information is provided here for a subset of transporters where these
are of significant pharmacological interest; further transporters are listed in the database
6113 ATP-binding cassette transporter family
6113 ABCA subfamily
6115 ABCB subfamily
6116 ABCC subfamily
6117 ABCD subfamily of peroxisomal ABC transporters
6118 ABCG subfamily
6119 F-type and V-type ATPases
6119 F-type ATPase
6120 V-type ATPase
6120 P-type ATPases
6121 Na+/K+-ATPases
6121 Ca2+-ATPases
6122 H+/K+-ATPases
6122 Cu+-ATPases
6122 Phospholipid-transporting ATPases
6123 Major facilitator superfamily (MFS) of transporters
6123 SLC superfamily of solute carriers
6124 SLC1 family of amino acid transporters
6124 Glutamate transporter subfamily
6126 Alanine/serine/cysteine transporter subfamily
6127 SLC2 family of hexose and sugar alcohol
6127 Class I transporters
6128 Class II transporters
6129 Proton-coupled inositol transporter
6129 SLC3 and SLC7 families of heteromeric
amino acid transporters (HATs)
6130 SLC3 family
6130 SLC7 family
6131 SLC4 family of bicarbonate transporters
6132 Anion exchangers
6132 Sodium-dependent HCO3
- transporters
6133 SLC5 family of sodium-dependent glucose
transporters
6134 Hexose transporter family
6135 Choline transporter
6136 Sodium iodide symporter, sodium-dependent
multivitamin transporter and sodium-coupled
monocarboxylate transporters
6137 Sodium myo-inositol cotransporter transporters
6138 SLC6 neurotransmitter transporter family
6138 Monoamine transporter subfamily
6139 GABA transporter subfamily
6141 Glycine transporter subfamily
6142 Neutral amino acid transporter subfamily
6144 SLC8 family of sodium/calcium exchangers
6145 SLC9 family of sodium/hydrogen exchangers
6145 SLC10 family of sodium-bile acid co-transporters
6147 SLC11 family of proton-coupled metal ion
transporters
6148 SLC12 family of cation-coupled chloride
transporters
6149 SLC13 family of sodium-dependent
sulphate/carboxylate transporters
6150 SLC14 family of facilitative urea transporters
6151 SLC15 family of peptide transporters
6152 SLC16 family of monocarboxylate transporters
6154 SLC17 phosphate and organic anion transporter
6154 family
6154 Type I sodium-phosphate co-transporters
6155 Sialic acid transporter
6155 Vesicular glutamate transporters (VGLUTs)
6156 Vesicular nucleotide transporter
6156 SLC18 family of vesicular amine transporters
6158 SLC19 family of vitamin transporters
6159 SLC20 family of sodium-dependent phosphate
transporters
6160 SLC22 family of organic cation and anion
transporters
6160 Organic cation transporters (OCT)
6161 Organic zwitterions/cation transporters (OCTN)
6162 Organic anion transporters (OATs)
6163 Urate transporter
– Orphan or poorly characterized SLC22
family members
6163 SLC23 family of ascorbic acid transporters
6164 SLC24 family of sodium/potassium/calcium
exchangers
6165 SLC25 family of mitochondrial transporters
6165 Mitochondrial di- and tri-carboxylic acid
transporter subfamily
6166 Mitochondrial amino acid transporter subfamily
6167 Mitochondrial phosphate transporters
6167 Mitochondrial nucleotide transporter subfamily
6168 Mitochondrial uncoupling proteins
6169 Miscellaneous SLC25 mitochondrial transporters
6170 SLC26 family of anion exchangers
6170 Selective sulphate transporters
6170 Chloride/bicarbonate exchangers
6171 Anion channels
6171 Other SLC26 anion exchangers
6172 SLC27 family of fatty acid transporters
6173 SLC28 and SLC29 families of nucleoside transporters
6173 SLC28 family
6174 SLC29 family
6176 SLC30 zinc transporter family
6176 SLC31 family of copper transporters
6177 SLC32 vesicular inhibitory amino acid transporter
6178 SLC33 acetylCoA transporter
6179 SLC34 family of sodium phosphate co-transporters
6180 SLC35 family of nucleotide sugar transporters
6181 SLC36 family of proton-coupled amino acid
transporters
6182 SLC37 family of phosphosugar/phosphate
exchangers
6182 SLC38 family of sodium-dependent neutral amino
6182 acid transporters
6183 System A-like transporters
6183 System N-like transporters
6184 Orphan SLC38 transporters
6185 SLC39 family of metal ion transporters
6186 SLC40 iron transporter
6187 SLC41 family of divalent cation transporters
6187 SLC42 family of Rhesus glycoprotein ammonium
transporters
6188 SLC43 family of large neutral amino acid
transporters
6189 SLC44 choline transporter-like family
6190 SLC45 family of putative sugar transporters
6191 SLC46 family of folate transporters
6192 SLC47 family of multidrug and toxin extrusion
transporters
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6192 SLC48 heme transporter
6193 SLC49 family of FLVCR-related heme transporters
6194 SLC50 sugar transporter
6195 SLC51 family of steroid-derived molecule
transporters
6195 SLC52 family of riboflavin transporters
6196 SLCO family of organic anion transporting
polypeptides
Searchable database: http://www.guidetopharmacology.org/index.jsp Transporters 6112
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ATP-binding cassette transporter family
Transporters! ATP-binding cassette transporter family
Overview: ATP-binding cassette transporters are ubiquitous
membrane proteins characterized by active ATP-dependent
movement of a range of substrates, including ions, lipids,
peptides, steroids. Individual subunits are typically made up of
two groups of 6TM-spanning domains, with two
nucleotide-binding domains (NBD). The majority of eukaryotic
ABC transporters are ‘full’ transporters incorporating both TM
and NBD entities. Some ABCs, notably the ABCD and ABCG
families are half-transporters with only a single membrane
spanning domain and one NBD, and are only functional as
homo- or heterodimers. Eukaryotic ABC transporters convey
substrates from the cytoplasm, either out of the cell or into
intracellular organelles. Their role in the efflux of exogenous
compounds, notably chemotherapeutic agents, has led to
considerable interest.
Comments: A further group of ABC transporter-like proteins
have been identified to lack membrane spanning regions and are
not believed to be functional transporters, but appear to have a
role in protein translation [88, 380]: ABCE1 (P61221, also known
as OABP or 2’-5’ oligoadenylate-binding protein); ABCF1
(Q8NE71, also known as ABC50 or TNF-α-stimulated ABC
protein); ABCF2 (Q9UG63, also known as iron-inhibited ABC
transporter 2) and ABCF3 (Q9NUQ8).
ABCA subfamily
Transporters! ATP-binding cassette transporter family! ABCA subfamily
Nomenclature ABCA1 ABCA3 ABCA4 ABCA5
Common
abreviation
ABC1, CERP ABC3, ABCC ABCR –
HGNC, UniProt ABCA1, O95477 ABCA3, Q99758 ABCA4, P78363 ABCA5, Q8WWZ7
Selective inhibitors probucol [156, 520] – – –
Searchable database: http://www.guidetopharmacology.org/index.jsp ABCA subfamily 6113
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(continued)
Nomenclature ABCA1 ABCA3 ABCA4 ABCA5
Comments Loss-of-function mutations are associated
with Tangier disease, in which plasma HDL
cholesterol levels are greatly reduced.
ABCA1 is a key player in cholesterol efflux
from macrophages to lipid-free apo-A1 in
a process known as reverse cholesterol
transport, a role that is important in
atherosclerosis. ABCA1 also controls apoE
lipidation, and has a role in Alzheimer’s
disease, including an impact on amyloid β
(APP, P05067) deposition and clearance.
ABCA1 is transcriptionally regulated by
Liver X Receptors (LXR) and Retinoic X
Receptor (RXR), which are being explored
as therapeutic targets for development of
agonists for treatment of metabolic and
neurodegenerative disorders [286].
Loss-of-function
mutations are
associated with
pulmonary surfactant
deficiency
Retinal-specific transporter of
N-retinylPE; loss-of-function mutations
are associated with childhood-onset
Stargardt disease, a juvenile onset
macular degenerative disease. The
earlier onset disease is often associated
with the more severe and deleterious
ABCA4 variants [173].
ABCA4 facilitates the clearance of
all-trans-retinal from photoreceptor
disc membranes following
photoexcitation. ABCA4 can also
transport N-11-cis-retinylidene-
phosphatidylethanolamine, the
Schiff-base adduct of 11-cis-retinal; loss
of function mutation cause a buildup
of lipofuscin, atrophy of the central
retina, and severe progressive loss in
vision [394].
ABCA5 is a lysosomal protein
whose loss of function
compromises integrity of
lysosomes and leads to
intra-endolysosomal accumulation
of cholesterol. It has recently been
associated with Congenital
Generalized Hypertrichosis
Terminalis (CGHT), a hair
overgrowth syndrome, in a
patient with a mutation in ABCA5
that significantly decreased its
expression [113].
Nomenclature ABCA6 ABCA7 ABCA12
HGNC, UniProt ABCA6, Q8N139 ABCA7, Q8IZY2 ABCA12, Q86UK0
Comments A recent genome wide association study identified
an ABCA6 variant associated with cholesterol levels
[557].
Genome wide association studies identify ABCA7
variants as associated with Alzheimer’s Disease
[232].
Reported to play a role in skin ceramide formation
[555]. A recent study shows that ABCA12
expression also impacts cholesterol efflux from
macrophages. ABCA12 is postulated to associate
with ABCA1 and LXR beta, and stabilize expression
of ABCA1. ABCA12 deficiency causes decreased
expression of Abca1, Abcg1 and Nr1h2 [171].
Comments: A number of structural analogues are not found in man: Abca14 (ENSMUSG00000062017); Abca15 (ENSMUSG00000054746); Abca16 (ENSMUSG00000051900) and Abca17
(ENSMUSG00000035435).
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ABCB subfamily
Transporters! ATP-binding cassette transporter family! ABCB subfamily
Nomenclature ABCB1 ABCB2 ABCB3 ABCB4 ABCB5
Common abreviation MDR1, PGP1 TAP1 TAP2 PGY3 –
HGNC, UniProt ABCB1, P08183 TAP1, Q03518 TAP2, Q03519 ABCB4, P21439 ABCB5, Q2M3G0
Comments Responsible for the
cellular export of many
therapeutic drugs. The
mouse and rat have two
Abcb1 genes (gene
names; Abcb1a and
Abcb1b) while the
human has only the one
gene, ABCB1.
Endoplasmic reticulum
peptide transporter,
possibly requires
heterodimerdimerization
with TAP2.
Endoplasmic reticulum
peptide transporter,
possibly as requires
heterodimerization with
TAP1.
Transports
phosphatidylcholine
from intracellular to
extracellular face of the
hepatocyte canalicular
membrane [375]
Multidrug resistance
protein in, and marker
of, melanoma cells [433]
Nomenclature ABCB6 ABCB7 ABCB8 ABCB9 ABCB10 ABCB11
Common
abreviation
MTABC3 ABC7 MABC1 TAPL MTABC2 ABC16
HGNC, UniProt ABCB6, Q9NP58 ABCB7, O75027 ABCB8, Q9NUT2 ABCB9, Q9NP78 ABCB10, Q9NRK6 ABCB11, O95342
Comments Putative mitochondrial
porphyrin transporter
[290]; other subcellular
localizations are
possible, such as the
plasma membrane, as a
specific determinant of
the Langereis blood
group system [227].
Mitochondrial;
reportedly essential
for haematopoiesis
[388]
Mitochondrial;
suggested to play a
role in
chemoresistance of
melanoma [142]
Reported to be
lysosomal [260]
Mitochondrial
location; the first
human ABC
transporter to have
a crystal structure
reported [448].
Loss-of-function
mutations are
associated with
progressive familial
intrahepatic
cholestasis type 2
[456]
Searchable database: http://www.guidetopharmacology.org/index.jsp ABCB subfamily 6115
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ABCC subfamily
Transporters! ATP-binding cassette transporter family! ABCC subfamily
Nomenclature ABCC1 ABCC2 ABCC3 ABCC4 ABCC5 ABCC6
Common
abreviation
MRP1 MRP2, cMOAT MRP3 MRP4 MRP5 MRP6
HGNC, UniProt ABCC1, P33527 ABCC2, Q92887 ABCC3, O15438 ABCC4, O15439 ABCC5, O15440 ABCC6, O95255
Comments Exhibits a broad
substrate specificity
[26], including
LTC4 (Km 97 nM
[309]) and
estradiol-17β-
glucuronide
[460].
Loss-of-function
mutations are
associated with
Dubin-Johnson
syndrome, in
which plasma levels
of conjugated
bilirubin are
elevated
(OMIM: 237500).
Transports
conjugates of
glutathione, sulfate
or glucuronide [51]
Although reported
to facilitate cellular
cyclic nucleotide
export, this role has
been questioned
[51]; reported to
export
prostaglandins in a
manner sensitive to
NSAIDS [403]
Although reported
to facilitate cellular
cyclic nucleotide
export, this role has
been questioned
[51]
Loss-of-function
mutations in
ABCC6 are
associated with
pseudoxanthoma
elasticum
(OMIM: 264800).
Nomenclature ATP-binding cassette, sub-family C(CFTR/MRP), member 8 ABCC9 ABCC11
Systematic
nomenclature
ABCC8 – –
Common
abreviation
SUR1 SUR2 MRP8
HGNC, UniProt ABCC8, Q09428 ABCC9, O60706 ABCC11, Q96J66
Selective
inhibitors
repaglinide (pIC50 7) [523] – –
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(continued)
Nomenclature ATP-binding cassette, sub-family C(CFTR/MRP), member 8 ABCC9 ABCC11
Comments The sulfonyurea drugs (acetohexamide, tolbutamide and glibenclamide)
appear to bind sulfonylurea receptors and it has been shown
experimentally that tritiated glibenclamide can be used to pull out a 140
kDa protein identified as SUR1 (now known as ABCC8) [402]. SUR2
(ABCC9) has also been identified [241]. However, this is not the full
mechanism of action and the functional channel has been characterised
as a hetero-octamer formed by four SUR and four Kir6.2 subunits, with
the Kir6.2 subunits forming the core ion pore and the SUR subunits
providing the regulatory properties [345]. Co-expression of Kir6.2 with
SUR1, reconstitutes the ATP-dependent K+ conductivity inhibited by the
sulfonyureas [241].
Associated with familial atrial
fibrillation, Cantu syndrome and
familial isolated dilated
cardiomyopathy.
Single nucleotide polymorphisms
distinguish wet vs. dry earwax
(OMIM: 117800); an association
between earwax allele and breast
cancer risk is reported in Japanese but
not European populations.
Comments: ABCC7 (also known as CFTR, a 12TM ABC
transporter-type protein, is a cAMP-regulated epithelial cell
membrane Cl- channel involved in normal fluid transport across
various epithelia and can be viewed in the Chloride channels
section of the Guide. ABCC8 (ENSG00000006071, also known as
SUR1, sulfonylurea receptor 1) and ABCC9 (ENSG00000069431,
also known as SUR2, sulfonylurea receptor 2) are unusual in that
they lack transport capacity but regulate the activity of particular
K+ channels (Kir6.1-6.2), conferring nucleotide sensitivity to
these channels to generate the canonical KATP channels.
ABCC13 (ENSG00000155288) is a possible pseudogene.
ABCD subfamily of peroxisomal ABC transporters
Transporters! ATP-binding cassette transporter family! ABCD subfamily of peroxisomal ABC transporters
Overview: This family of ‘half-transporters’ act as homo- or heterodimers to accumulate fatty acid-CoA esters into peroxisomes for oxidative metabolism [273].
Nomenclature ABCD1 ABCD2 ABCD3
Common
abreviation
ALDP ALDR PMP70
HGNC, UniProt ABCD1, P33897 ABCD2, Q9UBJ2 ABCD3, P28288
Comments Transports coenzyme A esters of very long chain fatty acids [558, 559];
loss-of-function mutations in ABCD1 are associated with
adrenoleukodystrophy (OMIM: 3001002).
Coenzyme A esters of very long chain unsaturated fatty
acids [558]
–
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Comments: ABCD4 (ENSG00000119688, also known as PMP69, PXMP1-L or P70R) appears to be located on the endoplasmic reticulum [271], with an unclear function. Loss-of-function mutations in
the gene encoding ALDP underlie the metabolic storage disorder X-linked adrenoleukodystrophy.
ABCG subfamily
Transporters! ATP-binding cassette transporter family! ABCG subfamily
Overview: This family of ‘half-transporters’ act as homo- or heterodimers; particularly ABCG5 and ABCG8 are thought to be obligate heterodimers. They are associated with cellular export of sterols
and phospholipids, as well as exogenous drugs (ABCG2).
Nomenclature ABCG1 ABCG2 ABCG4 ABCG5 ABCG8
Common abreviation ABC8 ABCP – – –
HGNC, UniProt ABCG1, P45844 ABCG2, Q9UNQ0 ABCG4, Q9H172 ABCG5, Q9H222 ABCG8, Q9H221
Comments Transports sterols and
choline phospholipids
[275]
Exhibits a broad
substrate specificity,
including urate and
haem, as well as multiple
synthetic compounds
[275]. The functional
transporter is likely to be
a homodimer, although
higher oligomeric states
have also been
proposed.
Putative functional
dependence on ABCG1
Transports phytosterols
and cholesterol; forms
an obligate heterodimer
with ABCG8.
Loss-of-function
mutations in ABCG5 are
associated with
sitosterolemia
(OMIM: 210250).
Transports phytosterols
and cholesterol; forms
an obligate heterodimer
with ABCG5.
Loss-of-function
mutations in ABCG8 are
associated with
sitosterolemia
(OMIM: 210250).
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F-type and V-type ATPases
Transporters! F-type and V-type ATPases
Overview: The F-type (ATP synthase) and the V-type (vacuolar
or vesicular proton pump) ATPases, although having distinct
subcellular locations and roles, exhibit marked similarities in
subunit structure and mechanism. They are both composed of a
‘soluble’ complex (termed F1 or V1) and a membrane complex
(Fo or Vo). Within each ATPase complex, the two individual
sectors appear to function as connected opposing rotary motors,
coupling catalysis of ATP synthesis or hydrolysis to proton
transport. Both the F-type and V-type ATPases have been
assigned enzyme commission number E.C. 3.6.3.14
F-type ATPase
Transporters! F-type and V-type ATPases! F-type ATPase
Overview: The F-type ATPase, also known as ATP synthase or
ATP phosphohydrolase (H+-transporting), is a mitochondrial
membrane-associated multimeric complex consisting of two
domains, an F0 channel domain in the membrane and an F1
domain extending into the lumen. Proton transport across the
inner mitochondrial membrane is used to drive the synthesis of
ATP, although it is also possible for the enzyme to function as an
ATPase. The ATP5O subunit (oligomycin sensitivity-conferring
protein, OSCP, (P48047)), acts as a connector between F1 and F0
motors.
The F1 motor, responsible for ATP turnover, has the subunit
composition α3β3γÆ.
The F0 motor, responsible for ion translocation, is complex in
mammals, with probably nine subunits centring on A, B, and C
subunits in the membrane, together with D, E, F2, F6, G2 and 8
subunits. Multiple pseudogenes for the F0 motor proteins have
been defined in the human genome.
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V-type ATPase
Transporters! F-type and V-type ATPases! V-type ATPase
Overview: The V-type ATPase is most prominently associated with lysosomes in mammals, but also appears to be expressed on the plasma membrane and neuronal synaptic vesicles.
The V1 motor, responsible for ATP turnover, has eight subunits with a composition of A-H.
TheV0 motor, responsible for ion translocation, has six subunits (a-e).
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P-type ATPases
Transporters! P-type ATPases
Overview: Phosphorylation-type ATPases (EC 3.6.3.-) are
associated with membranes and the transport of ions or
phospholipids. Characteristics of the family are the transient
phosphorylation of the transporters at an aspartate residue and
the interconversion between E1 and E2 conformations in the
activity cycle of the transporters, taken to represent
‘half-channels’ facing the cytoplasm and extracellular/luminal
side of the membrane, respectively.
Sequence analysis across multiple species allows the definition of
five subfamilies, P1-P5. The P1 subfamily includes heavy metal
pumps, such as the copper ATPases. The P2 subfamily includes
calcium, sodium/potassium and proton/potassium pumps. The
P4 and P5 subfamilies include putative phospholipid flippases.
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Na+/K+-ATPases
Transporters! P-type ATPases! Na+/K+-ATPases
Overview: The cell-surface Na+/K+-ATPase is an integral
membrane protein which regulates the membrane potential of
the cell by maintaining gradients of Na+ and K+ ions across the
plasma membrane, also making a small, direct contribution to
membrane potential, particularly in cardiac cells. For every
molecule of ATP hydrolysed, the Na+/K+-ATPase extrudes three
Na+ ions and imports two K+ ions. The active transporter is a
heteromultimer with incompletely defined stoichiometry,
possibly as tetramers of heterodimers, each consisting of one of
four large, ten TM domain catalytic α subunits and one of three
smaller, single TM domain glycoprotein β-subunits (see table).
Additional protein partners known as FXYD proteins (e.g.
FXYD2, P54710) appear to associate with and regulate the
activity of the pump.
Comments: Na+/K+-ATPases are inhibited by ouabain and cardiac glycosides, such as digoxin, as well as potentially endogenous cardiotonic steroids [23].
Ca2+-ATPases
Transporters! P-type ATPases! Ca2+-ATPases
Overview: The sarcoplasmic/endoplasmic reticulum
Ca2+-ATPase (SERCA) is an intracellular membrane-associated
pump for sequestering calcium from the cytosol into
intracellular organelles, usually associated with the recovery
phase following excitation of muscle and nerves.
The plasma membrane Ca2+-ATPase (PMCA) is a cell-surface
pump for extruding calcium from the cytosol, usually associated
with the recovery phase following excitation of cells. The active
pump is a homodimer, each subunit of which is made up of ten
TM segments, with cytosolic C- and N-termini and two large
intracellular loops.
Secretory pathway Ca2+-ATPases (SPCA) allow accumulation of
calcium and manganese in the Golgi apparatus.
Comments: The fungal toxin ochratoxin A has been described to activate SERCA in kidney microsomes [91]. Cyclopiazonic acid [440], thapsigargin [324] and BHQ are widely employed to block
SERCA. Thapsigargin has also been described to block the TRPV1 vanilloid receptor [485].
The stoichiometry of flux through the PMCA differs from SERCA, with the PMCA transporting 1 Ca2+ while SERCA transports 2 Ca2+.
Loss-of-function mutations in SPCA1 appear to underlie Hailey-Hailey disease [234].
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H+/K+-ATPases
Transporters! P-type ATPases! H+/K+-ATPases
Overview: The H+/K+ ATPase is a heterodimeric protein, made up of α and β subunits. The α subunit has 10 TM domains and exhibits catalytic and pore functions, while the β subunit has a single TM
domain, which appears to be required for intracellular trafficking and stabilising the α subunit. The ATP4A and ATP4B subunits are expressed together, while the ATP12A subunit is suggested to be
expressed with the β1 (ATP1B1) subunit of the Na+/K+-ATPase [383].
Comments: The gastric H+/K+-ATPase is inhibited by proton pump inhibitors used for treating excessive gastric acid secretion, including (R)-lansoprazole and a metabolite of esomeprazole.
Cu+-ATPases
Transporters! P-type ATPases! Cu+-ATPases
Overview: Copper-transporting ATPases convey copper ions across cell-surface and intracellular membranes. They consist of eight TM domains and associate with multiple copper chaperone proteins
(e.g. ATOX1, O00244).
Phospholipid-transporting ATPases
Transporters! P-type ATPases! Phospholipid-transporting ATPases
Overview: These transporters are thought to translocate the aminophospholipids phosphatidylserine and phosphatidylethanolamine from one side of the phospholipid bilayer to the other to generate
asymmetric membranes. They are also proposed to be involved in the generation of vesicles from intracellular and cell-surface membranes.
Comments: Loss-of-function mutations in ATP8B1 are
associated with type I familial intrahepatic cholestasis.
A further series of structurally-related proteins have been
identified in the human genome, with as yet undefined function,
including ATP13A1 (Q9HD20), ATP13A2 (Q9NQ11), ATP13A3
(Q9H7F0), ATP13A4 (Q4VNC1) and ATP13A5 (Q4VNC0).
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Major facilitator superfamily (MFS) of transporters
Prokaryotic sugar transporters!Major facilitator superfamily (MFS) of transporters
Nomenclature synaptic vesicle glycoprotein 2A
HGNC, UniProt SV2A, Q7L0J3
Inhibitors levetiracetam (pKi 5.8) [363] – Rat
SLC superfamily of solute carriers
Transporters! SLC superfamily of solute carriers
Overview: The SLC superfamily of solute carriers is the second
largest family of membrane proteins after G protein-coupled
receptors, but with a great deal fewer therapeutic drugs that
exploit them. As with the ABC transporters, however, they play a
major role in drug disposition and so can be hugely influential in
determining the clinical efficacy of particular drugs.
48 families are identified on the basis of sequence similarities,
but many of them overlap in terms of the solutes that they carry.
For example, amino acid accumulation is mediated by members
of the SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17, SLC32, SLC36,
SLC38 and SLC43. Further members of the SLC superfamily
regulate ion fluxes at the plasma membrane, or solute transport
into and out of cellular organelles.
Within the SLC superfamily, there is an abundance in diversity
of structure. Two families (SLC3 and SLC7) only generate
functional transporters as heteromeric partners, where one
partner is a single TM domain protein. Membrane topology
predictions for other families suggest 3, 4 6, 7, 8, 9, 10, 11, 12,
13, or 14 TM domains. Functionally, members may be divided
into those dependent on gradients of ions (particularly sodium,
chloride or protons), exchange of solutes or simple equilibrative
gating. For many members, the stoichiometry of transport is not
yet established. Furthermore, one family of transporters also
possess enzymatic activity (SLC27), while many members
function as ion channels (e.g. SLC1A7/EAAT5), which increases
the complexity of function of the SLC superfamily.
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SLC1 family of amino acid transporters
Transporters! SLC superfamily of solute carriers! SLC1 family of amino acid transporters
Overview: The SLC1 family of sodium dependent transporters includes the plasma membrane located glutamate transporters and the neutral amino acid transporters ASCT1 and ASCT2 [7, 32, 264,
265, 378].
Glutamate transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC1 family of amino acid transporters! Glutamate transporter subfamily
Overview: Glutamate transporters present the unusual
structural motif of 8TM segments and 2 re-entrant loops [208].
The crystal structure of a glutamate transporter homologue
(GltPh) from Pyrococcus horikoshii supports this topology and
indicates that the transporter assembles as a trimer, where each
monomer is a functional unit capable of substrate permeation
[53, 406, 533] reviewed by [254]). This structural data is in
agreement with the proposed quaternary structure for EAAT2
[185] and several functional studies that propose the monomer is
the functional unit [205, 284, 302, 418]. Recent evidence
suggests that EAAT3 and EAAT4 may assemble as heterotrimers
[362]. The activity of glutamate transporters located upon both
neurones (predominantly EAAT3, 4 and 5) and glia
(predominantly EAAT 1 and 2) serves, dependent upon their
location, to regulate excitatory neurotransmission, maintain low
ambient extracellular concentrations of glutamate (protecting
against excitotoxicity) and provide glutamate for metabolism
including the glutamate-glutamine cycle. The Na+/K+-ATPase
that maintains the ion gradients that drive transport has been
demonstrated to co-assemble with EAAT1 and EAAT2 [412].
Recent evidence supports altered glutamate transport and novel
roles in brain for splice variants of EAAT1 and EAAT2 [184, 303].
Three patients with dicarboxylic aminoaciduria (DA) were
recently found to have loss-of-function mutations in EAAT3 [24].
DA is characterized by excessive excretion of the acidic amino
acids glutamate and aspartate and EAAT3 is the predominant
glutamate/aspartate transporter in the kidney. Enhanced
expression of EAAT2 resulting from administration of β-lactam
antibiotics (e.g. ceftriaxone) is neuroprotective and occurs
through NF-B-mediated EAAT2 promoter activation [181, 306,
414] reviewed by [277]). PPARγ activation (e.g. by rosiglitazone)
also leads to enhanced expression of EAAT though promoter
activation [411]. In addition, several translational activators of
EAAT2 have recently been described [98] along with treatments
that increase the surface expression of EAAT2 (e.g. [301, 554]), or
prevent its down-regulation (e.g. [199]). A thermodynamically
uncoupled Cl- flux, activated by Na+ and glutamate [207, 265,
327] (Na+ and aspartate in the case of GltPh [417]), is sufficiently
large, in the instances of EAAT4 and EAAT5, to influence
neuronal excitability [476, 498]. Indeed, it has recently been
suggested that the primary function of EAAT5 is as a slow anion
channel gated by glutamate, rather than a glutamate transporter
[176].
Nomenclature Excitatory amino acid Excitatory amino acid Excitatory amino acid Excitatory amino acid Excitatory amino acid
transporter 1 transporter 2 transporter 3 transporter 4 transporter 5
Systematic
nomenclature
SLC1A3 SLC1A2 SLC1A1 SLC1A6 SLC1A7
Common
abreviation
EAAT1 EAAT2 EAAT3 EAAT4 EAAT5
HGNC, UniProt SLC1A3, P43003 SLC1A2, P43004 SLC1A1, P43005 SLC1A6, P48664 SLC1A7, O00341
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(continued)
Nomenclature Excitatory amino acid Excitatory amino acid Excitatory amino acid Excitatory amino acid Excitatory amino acid
transporter 1 transporter 2 transporter 3 transporter 4 transporter 5
Substrates DL-threo-β-hydroxyaspartate
(Ki 5.810
 5M) [444],
D-aspartic acid, L-trans-2,
4-pyrolidine dicarboxylate
D-aspartic acid,
DL-threo-β-hydroxyaspartate,
L-trans-2,
4-pyrolidine dicarboxylate
[285]
L-trans-2,
4-pyrolidine dicarboxylate,
DL-threo-β-hydroxyaspartate,
D-aspartic acid
D-aspartic acid,
DL-threo-β-hydroxyaspartate,
L-trans-2,
4-pyrolidine dicarboxylate
D-aspartic acid, L-trans-2,
4-pyrolidine dicarboxylate,
DL-threo-β-hydroxyaspartate
Endogenous
substrates
L-aspartic acid,
L-glutamic acid
L-glutamic acid,
L-aspartic acid
L-aspartic acid, L-cysteine
[543], L-glutamic acid
L-glutamic acid,
L-aspartic acid
L-aspartic acid,
L-glutamic acid
Stoichiometry Probably 3 Na+: 1 H+ : 1
glutamate (in): 1 K+ (out)
3 Na+: 1 H+ : 1
glutamate (in): 1 K+
(out) [311]
3 Na+: 1 H+ : 1
glutamate (in): 1 K+
(out) [542]
Probably 3 Na+: 1 H+ : 1
glutamate (in): 1 K+(out)
Probably 3 Na+: 1 H+ : 1
glutamate (in): 1 K+
(out)
Inhibitors UCPH-101 (membrane
potential assay) (pIC50 6.9)
[252], DL-TBOA (pKB 5)
[444]
WAY-213613 (pIC50 7.1)
[133], DL-TBOA (pKB
6.9) [444], SYM2081
(pKB 5.5) [492],
dihydrokainate (pKB 5),
threo-3-methylglutamate
(pKB 4.7) [492]
NBI-59159 (pIC50 7.1)
[131], L-β-BA
([3H]D-aspartate uptake
assay) (pKi 6.1) [150],
DL-TBOA (pIC50 5.1)
[446]
DL-TBOA (pKi 5.4) [443],
threo-3-methylglutamate
(pKi 4.3) [141]
DL-TBOA (pKi 5.5) [443]
Labelled ligands [3H]ETB-TBOA (Binding)
(pKd 7.8) [445] – Rat,
[3H](2S,4R)-4-methylglutamate,
[3H]D-aspartic acid,
[3H]L-aspartic acid
[3H]ETB-TBOA (Binding)
(pKd 7.8) [445] – Rat,
[3H](2S,4R)-4-methylglutamate,
[3H]D-aspartic acid,
[3H]L-aspartic acid
[3H]ETB-TBOA (Binding)
(pKd 6.5) [445] – Rat,
[3H]D-aspartic acid,
[3H]L-aspartic acid
[3H]ETB-TBOA (Binding)
(pKd 7.9) [445] – Rat,
[3H]D-aspartic acid,
[3H]L-aspartic acid
[3H]ETB-TBOA (Binding)
(pKd 7.6) [445] – Rat,
[3H]D-aspartic acid,
[3H]L-aspartic acid
Comments: The KB (or Ki) values reported, unless indicated
otherwise, are derived from transporter currents mediated by
EAATs expressed in voltage-clamped Xenopus laevis oocytes [141,
443, 444, 492]. KB (or Ki) values derived in uptake assays are
generally higher (e.g. [444]). In addition to acting as a poorly
transportable inhibitor of EAAT2, (2S,4R)-4-methylglutamate,
also known as SYM2081, is a competitive substrate for EAAT1
(KM = 54M; [235, 492]) and additionally is a potent kainate
receptor agonist [548] which renders the compound unsuitable
for autoradiographic localisation of EAATs [14]. Similarly, at
concentrations that inhibit EAAT2, dihydrokainate binds to
kainate receptors [444]. WAY-855 and WAY-213613 are both
non-substrate inhibitors with a preference for EAAT2 over EAAT3
and EAAT1 [132, 133]. NBI-59159 is a non-substrate inhibitor
with modest selectivity for EAAT3 over EAAT1 (>10-fold) and
EAAT2 (5-fold) [99, 130]. Analogously, L-β-threo-benzyl-aspartate
(L-β-BA) is a competitive non-substrate inhibitor that
preferentially blocks EAAT3 versus EAAT1, or EAAT2 [150].
[3H](2S,4R)-4-methylglutamate demonstrates low affinity
binding (KD

D
6.0 M) to EAAT1 and EAAT2 in rat brain
homogenates [15] and EAAT1 in murine astrocyte membranes
[13], whereas [3H]ETB-TBOA binds with high affinity to all
EAATs other than EAAT3 [445]. The novel isoxazole derivative
(-)-HIP-A may interact at the same site as TBOA and
preferentially inhibit reverse transport of glutamate [97].
Threo-3-methylglutamate induces substrate-like currents at
EAAT4, but does not elicit heteroexchange of [3H]-aspartate in
synaptosome preparations, inconsistent with the behaviour of a
substrate inhibitor [141]. Parawixin 1, a compound isolated from
the venom from the spider Parawixia bistriata is a selective
enhancer of the glutamate uptake through EAAT2 but not
through EAAT1 or EAAT3 [165, 166]. In addition to the agents
listed in the table, DL-threo-β-hydroxyaspartate and
L-trans-2,4-pyrolidine dicarboxylate act as non-selective
competitive substrate inhibitors of all EAATs. Zn2+ and
arachidonic acid are putative endogenous modulators of EAATs
with actions that differ across transporter subtypes (reviewed by
[491]).
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Alanine/serine/cysteine transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC1 family of amino acid transporters! Alanine/serine/cysteine transporter subfamily
Overview: ASC transporters mediate Na+-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr and their structure is predicted to be similar to that of the glutamate
transporters [16, 489]. ASCT1 and ASCT2 also exhibit thermodynamically uncoupled chloride channel activity associated with substrate transport [63, 541]. Whereas EAATs counter-transport K+ (see
above) ASCTs do not and their function is independent of the intracellular concentration of K+ [541].
Nomenclature Alanine/serine/cysteine transporter 1 Alanine/serine/cysteine transporter 2
Systematic nomenclature SLC1A4 SLC1A5
Common abreviation ASCT1 ASCT2
HGNC, UniProt SLC1A4, P43007 SLC1A5, Q15758
Endogenous substrates L-cysteine > L-alanine = L-serine > L-threonine L-alanine = L-serine = L-cysteine (low Vmax) = L-threonine = L-glutamine = L-asparagine
L-methionine 
D
glycine 
D
L-leucine > L-valine > L-glutamic acid (enhanced at low pH)
Stoichiometry 1 Na+: 1 amino acid (in): 1 Na+: 1 amino acid (out);
(homo-, or hetero-exchange; [542])
1 Na+: 1 amino acid (in): 1 Na+: 1 amino acid (out); (homo-, or hetero-exchange; [61])
Inhibitors – p-nitrophenyl glutamyl anilide (pKi 4.3) [151] – Rat, benzylcysteine (pKi 3.1) [206],
benzylserine (pKi 3) [206]
Comments: The substrate specificity of ASCT1 may extend to L-proline and trans-4-hydroxy-proline [386]. At low pH ( 5.5) both ASCT1 and ASCT2 are able to exchange acidic amino acids such as
L-cysteate and glutamate [466, 489]. In addition to the inhibitors tabulated above, HgCl2, methylmercury and mersalyl, at low micromolar concentrations, non-competitively inhibit ASCT2 by covalent
modificiation of cysteine residues [372].
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SLC2 family of hexose and sugar alcohol transporters
Transporters! SLC superfamily of solute carriers! SLC2 family of hexose and sugar alcohol transporters
Overview: The SLC2 family transports D-glucose, D-fructose, inositol (e.g. myo-inositol) and related hexoses. Three classes of glucose transporter can be identified, separating GLUT1-4 and 14, GLUT6,
8, 10 and 12; and GLUT5, 7, 9 and 11. Modelling suggests a 12 TM membrane topology, with intracellular termini, with functional transporters acting as homodimers or homotetramers.
Class I transporters
Transporters! SLC superfamily of solute carriers! SLC2 family of hexose and sugar alcohol transporters! Class I transporters
Overview: Class I transporters are able to transport D-glucose, but not D-fructose, in the direction of the concentration gradient and may be inhibited non-selectively by phloretin and cytochalasin B.
GLUT1 is the major glucose transporter in brain, placenta and erythrocytes, GLUT2 is found in the pancreas, liver and kidneys, GLUT3 is neuronal and placental, while GLUT4 is the insulin-responsive
transporter found in skeletal muscle, heart and adipose tissue. GLUT14 appears to result from gene duplication of GLUT3 and is expressed in the testes [521].
Nomenclature Glucose transporter 1 Glucose transporter 2 Glucose transporter 3 Glucose transporter 4
Glucose transporter 14
Systematic
nomenclature
SLC2A1 SLC2A2 SLC2A3 SLC2A4 SLC2A14
Common
abreviation
GLUT1 GLUT2 GLUT3 GLUT4 GLUT14
HGNC,
UniProt
SLC2A1, P11166 SLC2A2, P11168 SLC2A3, P11169 SLC2A4, P14672 SLC2A14, Q8TDB8
Substrates D-glucosamine (D-glucose =
D-glucosamine) [487],
dehydroascorbic acid [39],
D-glucose (D-glucose =
D-glucosamine) [487]
D-glucosamine
(D-glucosamine > D-glucose)
[487], D-glucose
(D-glucosamine > D-glucose)
[487]
D-glucose D-glucosamine
(D-glucosamine  D-glucose)
[487], D-glucose
(D-glucosamine  D-glucose)
[487]
–
Labelled
ligands
[3H]2-deoxyglucose [3H]2-deoxyglucose [3H]2-deoxyglucose [3H]2-deoxyglucose –
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Class II transporters
Transporters! SLC superfamily of solute carriers! SLC2 family of hexose and sugar alcohol transporters! Class II transporters
Overview: Class II transporters transport D-fructose and appear to be insensitive to cytochalasin B. Class II transporters appear to be predominantly intracellularly located.
Nomenclature Glucose transporter 5 Glucose transporter 7 Glucose transporter 9 Glucose transporter 11
Systematic nomenclature SLC2A5 SLC2A7 SLC2A9 SLC2A11
Common abreviation GLUT5 GLUT7 GLUT9 GLUT11
HGNC, UniProt SLC2A5, P22732 SLC2A7, Q6PXP3 SLC2A9, Q9NRM0 SLC2A11, Q9BYW1
Substrates D-fructose (D-fructose >
D-glucose) [67], D-glucose
(D-fructose > D-glucose) [67]
D-fructose [81], D-glucose [81] D-fructose [75], uric acid [75] D-fructose [332], D-glucose
[122]
Nomenclature Glucose transporter 6 Glucose transporter 8 Glucose transporter 10 Glucose transporter 12
Systematic nomenclature SLC2A6 SLC2A8 SLC2A10 SLC2A12
Common abreviation GLUT6 GLUT8 GLUT10 GLUT12
HGNC, UniProt SLC2A6, Q9UGQ3 SLC2A8, Q9NY64 SLC2A10, O95528 SLC2A12, Q8TD20
Substrates – D-glucose [238] dehydroascorbic acid [308],
D-glucose [308]
D-glucose [409]
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Proton-coupled inositol transporter
Transporters! SLC superfamily of solute carriers! SLC2 family of hexose and sugar alcohol transporters! Proton-coupled inositol transporter
Overview: Proton-coupled inositol transporters are expressed predominantly in the brain and can be inhibited by phloretin and cytochalasin B [487].
Nomenclature Proton myo-inositol cotransporter
Systematic nomenclature SLC2A13
Common abreviation HMIT
HGNC, UniProt SLC2A13, Q96QE2
Substrates D-chiro-inositol [487], myo-inositol [487], scyllo-inositol [487], muco-inositol [487]
Stoichiometry 1 H+ : 1 inositol (in) [118]
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SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)
Transporters! SLC superfamily of solute carriers! SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)
Overview: The SLC3 and SLC7 families combine to generate functional transporters, where the subunit composition is a disulphide-linked combination of a heavy chain (SLC3 family) with a light
chain (SLC7 family).
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SLC3 family
Transporters! SLC superfamily of solute carriers! SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)! SLC3 family
Overview: SLC3 family members are single TM proteins with extensive glycosylation of the exterior C-terminus, which heterodimerize with SLC7 family members in the endoplasmic reticulum and
assist in the plasma membrane localization of the transporter.
SLC7 family
Transporters! SLC superfamily of solute carriers! SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)! SLC7 family
Overview: SLC7 family members may be divided into two major groups: cationic amino acid transporters (CATs) and glycoprotein-associated amino acid transporters (gpaATs).
Cationic amino acid transporters are 14 TM proteins, which mediate pH- and sodium-independent transport of cationic amino acids (system y+), apparently as an exchange mechanism. These
transporters are sensitive to inhibition by N-ethylmaleimide.
Nomenclature High affinity cationic amino acid Low affinity cationic amino acid Cationic amino acid L-type amino acid transporter 1
transporter 1 transporter 2 transporter 3
Systematic nomenclature SLC7A1 SLC7A2 SLC7A3 SLC7A5
Common abreviation CAT1 CAT2 CAT3 LAT1
HGNC, UniProt SLC7A1, P30825 SLC7A2, P52569 SLC7A3, Q8WY07 SLC7A5, Q01650
Substrates L-ornithine, L-arginine, L-lysine,
L-histidine
L-ornithine, L-arginine, L-lysine,
L-histidine
L-ornithine, L-arginine, L-lysine –
Nomenclature L-type amino acid transporter 2 y+L amino acid transporter 1 y+L amino acid transporter 2 b0,+-type amino acid transporter 1
Systematic nomenclature SLC7A8 SLC7A7 SLC7A6 SLC7A9
Common abreviation LAT2 y+LAT1 y+LAT2 b0,+AT
HGNC, UniProt SLC7A8, Q9UHI5 SLC7A7, Q9UM01 SLC7A6, Q92536 SLC7A9, P82251
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Nomenclature Asc-type amino acid transporter 1 Cystine/glutamate transporter AGT1
Systematic nomenclature SLC7A10 SLC7A11 SLC7A13
Common abreviation Asc-1 xCT –
HGNC, UniProt SLC7A10, Q9NS82 SLC7A11, Q9UPY5 SLC7A13, Q8TCU3
Comments: CAT4 appears to be non-functional in heterologous
expression [516], while SLC7A14 has yet to be characterized.
Glycoprotein-associated amino acid transporters are 12 TM
proteins, which heterodimerize with members of the SLC3
family to act as cell-surface amino acid exchangers.
Heterodimers between 4F2hc and LAT1 or LAT2 generate
sodium-independent system L transporters. LAT1 transports
large neutral amino acids including branched-chain and
aromatic amino acids as well as miglustat, whereas LAT2
transports most of the neutral amino acids.
Heterodimers between 4F2hc and y+LAT1 or y+LAT2 generate
transporters similar to the system y+L , which transport cationic
(L-arginine, L-lysine, L-ornithine) amino acids independent of
sodium and neutral (L-leucine, L-isoleucine, L-methionine,
L-glutamine) amino acids in a partially sodium-dependent
manner. These transporters are N-ethylmaleimide-insensitive.
Heterodimers between rBAT and b0,+AT appear to mediate
sodium-independent system b0,+ transport of most of the
neutral amino acids and cationic amino acids (L-arginine,
L-lysine and L-ornithine).
Asc-1 appears to heterodimerize with 4F2hc to allow the
transport of small neutral amino acids (such as L-alanine,
L-serine, L-threonine, L-glutamine and glycine), as well as
D-serine, in a sodium-independent manner.
xCT generates a heterodimer with 4F2hc for a system x-e-c
transporter that mediates the sodium-independent exchange of
L-cystine and L-glutamic acid.
AGT has been conjugated with SLC3 members as fusion proteins
to generate functional transporters, but the identity of a native
heterodimer has yet to be ascertained.
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SLC4 family of bicarbonate transporters
Transporters! SLC superfamily of solute carriers! SLC4 family of bicarbonate transporters
Overview: Together with the SLC26 family, the SLC4 family of
transporters subserve anion exchange, principally of chloride
and bicarbonate (HCO3
-), but also carbonate and hydrogen
sulphate (HSO4
-). SLC4 family members regulate bicarbonate
fluxes as part of carbon dioxide movement, chyme neutralization
and reabsorption in the kidney.
Within the family, subgroups of transporters are identifiable: the
electroneutral sodium-independent Cl-/HCO3
- transporters
(AE1, AE2 and AE3), the electrogenic sodium-dependent HCO3
-
transporters (NBCe1 and NBCe2) and the electroneutral HCO3
-
transporters (NBCn1 and NBCn2). Topographical information
derives mainly from study of AE1, abundant in erythrocytes,
which suggests a dimeric or tetrameric arrangement, with
subunits made up of 13 TM domains and re-entrant loops at
TM9/10 and TM11/12. The N terminus exhibits sites for
interaction with multiple proteins, including glycolytic enzymes,
haemoglobin and cytoskeletal elements.
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Anion exchangers
Transporters! SLC superfamily of solute carriers! SLC4 family of bicarbonate transporters! Anion exchangers
Nomenclature Anion exchange protein 1 Anion exchange protein 2 Anion exchange protein 3 Anion exchange protein 4
Systematic nomenclature SLC4A1 SLC4A2 SLC4A3 SLC4A9
Common abreviation AE1 AE2 AE3 AE4
HGNC, UniProt SLC4A1, P02730 SLC4A2, P04920 SLC4A3, P48751 SLC4A9, Q96Q91
Endogenous substrates HCO3
-, Cl- Cl-, HCO3
- Cl-, HCO3
- –
Stoichiometry 1 Cl- (in) : 1 HCO3
- (out) 1 Cl- (in) : 1 HCO3
- (out) 1 Cl- (in) : 1 HCO3
- (out) –
Sodium-dependent HCO3
- transporters
Transporters! SLC superfamily of solute carriers! SLC4 family of bicarbonate transporters! Sodium-dependent HCO3
- transporters
Nomenclature Electrogenic sodium bicarbonate Electrogenic sodium bicarbonate Electroneutral sodium bicarbonate
cotransporter 1 cotransporter 4 cotransporter 1
Systematic nomenclature SLC4A4 SLC4A5 SLC4A7
Common abreviation NBCe1 NBCe2 NBCn1
HGNC, UniProt SLC4A4, Q9Y6R1 SLC4A5, Q9BY07 SLC4A7, Q9Y6M7
Endogenous substrates NaHCO3
- NaHCO3
- NaHCO3
-
Stoichiometry 1 Na+ : 2/3 HCO3
- (out) or 1 Na+ : CO3
2* 1 Na+ : 2/3 HCO3
- (out) or 1 Na+ : CO3
2* 1 Na+ : 1 HCO3
- (out) or 1 Na+ : CO3
2*
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Nomenclature Electroneutral sodium bicarbonate NBCBE NaBC1
cotransporter 2
Systematic nomenclature SLC4A10 SLC4A8 SLC4A11
Common abreviation NBCn2 NDCBE BTR1
HGNC, UniProt SLC4A10, Q6U841 SLC4A8, Q2Y0W8 SLC4A11, Q8NBS3
Endogenous substrates NaHCO3
- NaHCO3
-, Cl- Cl-, NaHCO3
-
Stoichiometry 1 Na+ : 1 HCO3
- (out) or 1 Na : CO3
2* 1 Na+ : 2HCO3
- (in) : 1 Cl- (out) –
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SLC5 family of sodium-dependent glucose transporters
Transporters! SLC superfamily of solute carriers! SLC5 family of sodium-dependent glucose transporters
Overview: The SLC5 family of sodium-dependent glucose transporters includes, in mammals, the Na+/substrate co-transporters for glucose (e.g. choline), D-glucose, monocarboxylates, myo-inositol
and I- [159, 179, 518, 519]. Members of the SLC5 and SLC6 families, along with other unrelated Na+ cotransporters (i.e. Mhp1 and BetP), share a common structural core that contains an inverted
repeat of 5TM α-helical domains [2].
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Hexose transporter family
Transporters! SLC superfamily of solute carriers! SLC5 family of sodium-dependent glucose transporters! Hexose transporter family
Overview: Detailed characterisation of members of the hexose
transporter family is limited to SGLT1, 2 and 3, which are all
inhibited in a competitive manner by phlorizin, a natural
dihydrocholine glucoside, that exhibits modest selectivity
towards SGLT2 (see [518] for an extensive review). SGLT1 is
predominantly expressed in the small intestine, mediating the
absorption of glucose (e.g. D-glucose), but also occurs in the
brain, heart and in the late proximal straight tubule of the
kidney. The expression of SGLT2 is almost exclusively restricted
to the early proximal convoluted tubule of the kidney, where it is
largely responsible for the renal reabsorption of glucose. SGLT3 is
not a transporter but instead acts as a glucosensor generating an
inwardly directed flux of Na+ that causes membrane
depolarization [120].
Nomenclature Sodium/glucose Sodium/glucose Low affinity sodium- Sodium/glucose Sodium/glucose
cotransporter 1 cotransporter 2 glucose cotransporter cotransporter 4 cotransporter 5
Systematic
nomenclature
SLC5A1 SLC5A2 SLC5A4 SLC5A9 SLC5A10
Common
abreviation
SGLT1 SGLT2 SGLT3 SGLT4 SGLT5
HGNC, UniProt SLC5A1, P13866 SLC5A2, P31639 SLC5A4, Q9NY91 SLC5A9, Q2M3M2 SLC5A10, A0PJK1
Substrates D-galactose [501], α-MDG
[501], D-glucose [501]
α-MDG, D-glucose D-glucose [501],
1-deoxynojirimycin-1-sulfonic acid
[501], N-ethyl-1-deoxynojirimycin
[501], miglustat [501], miglitol [501],
1-deoxynojirimycin [501]
D-glucose,
D-mannose, α-MDG
D-galactose,
D-glucose
Stoichiometry 2 Na+ : 1 glucose [266] 1 Na+ : 1 glucose [236] – – –
Inhibitors sotagliflozin (pIC50 7.4)
[538], dapagliflozin (pIC50
6.4) [313], canagliflozin
(pIC50 6.2) [316],
remogliflozin (pKi 5.3)
[172], empagliflozin (pIC50
5.1) [204], sergliflozin (pKi
5.1) [272]
empagliflozin (pIC50 8.5)
[204], canagliflozin (pIC50
8.4) [316], remogliflozin
(pKi 7.9) [172], sergliflozin
(pKi 6.8) [272]
– – –
Selective
inhibitors
– dapagliflozin (pIC50 9.3)
[269]
– – –
Comments – – ’sodium/glucose cotransporter 3’ is a
misnomer since SGLT3 is a
glucosensor.
– –
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Comments: Recognition and transport of substrate by SGLTs
requires that the sugar is a pyranose. De-oxyglucose derivatives
have reduced affinity for SGLT1, but the replacement of the sugar
equatorial hydroxyl group by fluorine at some positions,
excepting C2 and C3, is tolerated (see [518] for a detailed
quantification). Although SGLT1 and SGLT2 have been described
as high- and low-affinity sodium glucose co-transporters,
respectively, recent work suggests that they have a similar
affinity for glucose under physiological conditions [236].
Selective blockers of SGLT2, and thus blocking 50% of renal
glucose reabsorption, are in development for the treatment of
diabetes (e.g. [80]).
Choline transporter
Transporters! SLC superfamily of solute carriers! SLC5 family of sodium-dependent glucose transporters! Choline transporter
Overview: The high affinity, hemicholinium-3-sensitive,
choline transporter (CHT) is expressed mainly in cholinergic
neurones on nerve cell terminals and synaptic vesicles
(keratinocytes being an additional location). In autonomic
neurones, expression of CHT requires an activity-dependent
retrograde signal from postsynaptic neurones [291]. Through
recapture of choline generated by the hydrolysis of ACh by
acetylcholinesterase, CHT serves to maintain acetylcholine
synthesis within the presynaptic terminal [159]. Homozygous
mice engineered to lack CHT die within one hour of birth as a
result of hypoxia arising from failure of transmission at the
neuromuscular junction of the skeletal muscles that support
respiration [158]. A low affinity choline uptake mechanism that
remains to be identified at the molecular level may involve
multiple transporters. In addition, a family of choline
transporter-like (CTL) proteins, (which are members of the SLC44
family) with weak Na+ dependence have been described [477].
Nomenclature CHT
Systematic nomenclature SLC5A7
HGNC, UniProt SLC5A7, Q9GZV3
Substrates triethylcholine
Endogenous substrates choline
Stoichiometry Na+ : choline (variable stoichimetry); modulated by extracellular Cl- [251]
Selective inhibitors hemicholinium-3 (pKi 7–8) [370]
Labelled ligands [3H]hemicholinium-3 (pKd 8.2–8.4)
Comments: Ki and KD values for hemicholinium-3 listed in the table are for human CHT expressed in Xenopus laevis oocytes [371], or COS-7 cells [12]. Hemicholinium mustard is a substrate for CHT
that causes covalent modification and irreversible inactivation of the transporter. Several exogenous substances (e.g. triethylcholine) that are substrates for CHT act as precursors to cholinergic false
transmitters.
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Sodium iodide symporter, sodium-dependent multivitamin transporter
and sodium-coupled monocarboxylate transporters
Transporters! SLC superfamily of solute carriers! SLC5 family of sodium-dependent glucose transporters!
Sodium iodide symporter, sodium-dependent multivitamin transporter and sodium-coupled monocarboxylate transporters
Overview: The sodium-iodide symporter (NIS) is an iodide
transporter found principally in the thyroid gland where it
mediates the accumulation of I- within thyrocytes. Transport of
I- by NIS from the blood across the basolateral membrane
followed by apical efflux into the colloidal lumen, mediated at
least in part by pendrin (SLC22A4), and most likely not SMCT1
(SLC5A8) as once thought, provides the I- required for the
synthesis of the thyroid hormones triiodothyronine
(triiodothyronine) and thyroxine (T4) [42]. NIS is also expressed
in the salivary glands, gastric mucosa, intestinal enterocytes and
lactating breast. NIS mediates I- absorption in the intestine and
I- secretion into the milk. SMVT is expressed on the apical
membrane of intestinal enterocytes and colonocytes and is the
main system responsible for biotin (vitamin H) and
pantothenic acid (vitamin B5) uptake in humans [422]. SMVT
located in kidney proximal tubule epithelial cells mediates the
reabsorption of biotin and pantothenic acid. SMCT1 (SLC5A8),
which transports a wide range of monocarboxylates, is expressed
in the apical membrane of epithelia of the small intestine, colon,
kidney, brain neurones and the retinal pigment epithelium [179].
SMCT2 (SLC5A12) also localises to the apical membrane of
kidney, intestine, and colon, but in the brain and retina is
restricted to astrocytes and Müller cells, respectively [179].
SMCT1 is a high-affinity transporter whereas SMCT2 is a
low-affinity transporter. The physiological substrates for SMCT1
and SMCT2 are lactate (L-lactic acid and D-lactic acid),
pyruvic acid, propanoic acid, and nicotinic acid in non-colonic
tissues such as the kidney. SMCT1 is also likely to be the
principal transporter for the absorption of nicotinic acid
(vitamin B3) in the intestine and kidney [197]. In the small
intestine and colon, the physiological substrates for these
transporters are nicotinic acid and the short-chain fatty acids
acetic acid, propanoic acid, and butyric acid that are produced by
bacterial fermentation of dietary fiber [350]. In the kidney,
SMCT2 is responsible for the bulk absorption of lactate because
of its low-affinity/high-capacity nature. Absence of both
transporters in the kidney leads to massive excretion of lactate in
urine and consequently drastic decrease in the circulating levels
of lactate in blood [470]. SMCT1 also functions as a tumour
suppressor in the colon as well as in various other non-colonic
tissues [180]. The tumour-suppressive function of SMCT1 is
based on its ability to transport pyruvic acid, an inhibitor of
histone deacetylases, into cells in non-colonic tissues [471]; in
the colon, the ability of SMCT1 to transport butyric acid and
propanoic acid, also inhibitors of histone deacetylases, underlies
the tumour-suppressive function of this transporter [179, 180,
213]. The ability of SMCT1 to promote histone acetylase
inhibition through accumulation of butyric acid and
propanoic acid in immune cells is also responsible for
suppression of dendritic cell development in the colon [451].
Nomenclature NIS SMVT SMCT1 SMCT2
Systematic
nomenclature
SLC5A5 SLC5A6 SLC5A8 SLC5A12
HGNC, UniProt SLC5A5, Q92911 SLC5A6, Q9Y289 SLC5A8, Q8N695 SLC5A12, Q1EHB4
Substrates ClO4
-, SCN-, I-, NO3
-,
pertechnetate
lipoic acid [556], pantothenic acid
[556], I- [556], biotin [556]
propanoic acid, 3-bromopyruvate,
pyroglutamic acid, nicotinic acid, D-lactic acid,
β-D-hydroxybutyric acid, L-lactic acid,
salicylic acid, dichloroacetate, butyric acid,
α-ketoisocaproate, pyruvic acid,
acetoacetic acid, benzoate,
γ-hydroxybutyric acid,
2-oxothiazolidine-4-carboxylate, acetic acid,
β-L-hydroxybutyric acid, 5-aminosalicylate
pyruvic acid,
L-lactic acid,
nicotinic acid
Stoichiometry 2Na+ : 1 I- [149]; 1Na+ : 1
ClO4
- [123]
2Na+ : 1 biotin (or pantothenic acid)
[390]
2Na+ : 1 monocarboxylate [94] –
Inhibitors – – fenoprofen (pIC50 4.6) [248], ibuprofen (pIC50
4.2) [248], ketoprofen (pIC50 3.9) [248]
–
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Comments: I-, ClO4
-, thiocyanate and NO3
- are competitive substrate inhibitors of NIS [123]. Lipoic acid appears to act as a competitive substrate inhibitor of SMVT [505] and the anticonvulsant
drugs primidone and carbamazepine competitively block the transport of biotin by brush border vesicles prepared from human intestine [423].
Sodium myo-inositol cotransporter transporters
Transporters! SLC superfamily of solute carriers! SLC5 family of sodium-dependent glucose transporters! Sodium myo-inositol cotransporter transporters
Overview: Three different mammalian myo-inositol
cotransporters are currently known; two are the Na+-coupled
SMIT1 and SMIT2 tabulated below and the third is
proton-coupled HMIT (SLC2A13). SMIT1 and SMIT2 have a
widespread and overlapping tissue location but in polarized cells,
such as the Madin-Darby canine kidney cell line, they segregate
to the basolateral and apical membranes, respectively [41]. In the
nephron, SMIT1 mediates myo-inositol uptake as a ‘compatible
osmolyte’ when inner medullary tubules are exposed to increases
in extracellular osmolality, whilst SMIT2 mediates the
reabsorption of myo-inositol from the filtrate. In some species
(e.g. rat, but not rabbit) apically located SMIT2 is responsible for
the uptake of myo-inositol from the intestinal lumen [11].
Nomenclature SMIT SGLT6
Systematic nomenclature SLC5A3 SLC5A11
Common abreviation SMIT1 SMIT2
HGNC, UniProt SLC5A3, P53794 SLC5A11, Q8WWX8
Substrates myo-inositol, scyllo-inositol > L-fucose > L-xylose > L-glucose, D-glucose,
α-MDG > D-galactose, D-fucose > D-xylose [214]
myo-inositol = D-chiro-inositol> D-glucose > D-xylose > L-xylose [95]
Stoichiometry 2 Na+ :1 myo-inositol [214] 2 Na+ :1 myo-inositol [55]
Inhibitors phlorizin [95] phlorizin (pKi 4.1) [95]
Comments: The data tabulated are those for dog SMIT1 and rabbit SMIT2. SMIT2 transports D-chiro-inositol, but SMIT1 does not. In addition, whereas SMIT1 transports both D-xylose and L-xylose and
D-fucose and L-fucose, SMIT2 transports only the D-isomers of these sugars [95, 214]. Thus the substrate specificities of SMIT1 (for L-fucose) and SMIT2 (for D-chiro-inositol) allow discrimination
between the two SMITs. Human SMIT2 appears not to transport glucose [318].
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SLC6 neurotransmitter transporter family
Transporters! SLC superfamily of solute carriers! SLC6 neurotransmitter transporter family
Overview: Members of the solute carrier family 6 (SLC6) of
sodium- and (sometimes chloride-) dependent neurotransmitter
transporters [64, 83, 292] are primarily plasma membrane
located and may be divided into four subfamilies that transport
monoamines, GABA, glycine and neutral amino acids, plus the
related bacterial NSS transporters [424]. The members of this
superfamily share a structural motif of 10 TM segments that has
been observed in crystal structures of the NSS bacterial homolog
LeuTAa, a Na
+-dependent amino acid transporter from Aquiflex
aeolicus [527] and in several other transporter families
structurally related to LeuT [167].
Monoamine transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC6 neurotransmitter transporter family!Monoamine transporter subfamily
Overview: Monoamine neurotransmission is limited by perisynaptic transporters. Presynaptic monoamine transporters allow recycling of synaptically released noradrenaline, dopamine and
5-hydroxytryptamine.
Nomenclature NET DAT SERT
Systematic nomenclature SLC6A2 SLC6A3 SLC6A4
HGNC, UniProt SLC6A2, P23975 SLC6A3, Q01959 SLC6A4, P31645
Substrates MPP+, methamphetamine, amphetamine MPP+, methamphetamine, amphetamine MDMA, p-chloroamphetamine
Endogenous substrates dopamine, (-)-adrenaline, (-)-noradrenaline dopamine, (-)-adrenaline, (-)-noradrenaline 5-hydroxytryptamine
Stoichiometry 1 noradrenaline: 1 Na+:1 Cl- [211] 1 dopamine: 1-2 Na+: 1 Cl- [210] 1 5-HT:1 Na+:1 Cl- (in), + 1 K+ (out) [465]
Inhibitors milnacipran (pIC50 9.1) [490], atomoxetine
(pKd 8.7) [72], desipramine (pKi 8.7)
[368], lofepramine (pKi 8.3) [468],
duloxetine (pKi 8.2) [382], nortriptyline
(pKi 8.2) [192], amoxapine (pKi 7.9) [21],
imipramine (pKi 7.8), doxepin (pKi 7.5)
[21], clomipramine (pKd 7.4) [468],
levomilnacipran (pIC50 7.4) [499],
dosulepin (pKi 7.3) [468], dexamfetamine
(pKi 7) [17], amitriptyline (pKi 6.5) [17],
nefazodone (pKd 6.4) [72], bupropion (pKi
6.4) [296], trimipramine (pKi 5.6) [468],
tapentadol (pKi 5.1) [484]
cocaine (pIC50 7.1) [74] – Rat,
dexamfetamine (pKi 7) [17], bupropion
(pIC50 6.3) [73], atomoxetine (pKd 6) [72],
trimipramine (pKi 5.4) [468], nomifensine
vilazodone (pIC50 8.8–9.3) [108, 226],
vortioxetine (pKi 8.8) [30], duloxetine (pKi
8.3) [163], nortriptyline (pKi 8.2) [21],
dosulepin (pKi 8.1) [468], atomoxetine
(pKd 8.1) [72], desvenlafaxine (pKi 7.8)
[128], amoxapine (pKi 7.7) [21],
imipramine (pKi 7.7) [462], milnacipran
(pIC50 7.3) [490], lofepramine (pKi 7.2)
[468], trimipramine (pKi 6.8) [468],
desipramine (pKi 6.8) [377], nefazodone
(pKd 6.7) [72], levomilnacipran (pIC50 6.5)
[499]
(Sub)family-selective inhibitors desvenlafaxine (pKi <6.2) [128],
sibutramine (pKi 5.2) [21]
sibutramine (pKi 6.3) [21] sibutramine (pKi 6) [21]
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(continued)
Nomenclature NET DAT SERT
Selective inhibitors mazindol (pKi 8.9), protriptyline (pIC50
8.8) [352], nisoxetine (pKi 8.4),
protriptyline (pKi 8.2) [320], nomifensine
(pKi 8.1), reboxetine (pKi 8) [517],
maprotiline (pKi 7.9) [225],
methylphenidate (pIC50 7.2)
mazindol (pKi 8), WIN35428 (pKi 7.9)
[404], GBR12935 (pKi 7.6),
dexmethylphenidate (pKi 7.6) [297],
methylphenidate (pIC50 7.1) [170]
clomipramine (pKi 9.7) [468], paroxetine
(pKi 9.6) [468], clomipramine (pKd 9.6)
[468], sertraline (pKi 9.1), escitalopram
(pIC50 9) [413], dapoxetine (pIC50 8.9)
[186], fluvoxamine (pKd 8.7) [468],
fluoxetine (pKi 8.5) [468], citalopram (pKi
8.4) [34], protriptyline (pKd 7.7) [468],
venlafaxine (pIC50 7.6) [419], amitriptyline
(pKi 6.8) [17]
Labelled ligands [3H]mazindol (Inhibitor) (pKd 9.3) [396] –
Rat, [3H]nisoxetine (Inhibitor) (pKd 8.4)
[3H]GBR12935 (Inhibitor) (pKd 8.5) [391],
[3H]WIN35428 (Inhibitor) (pKd 8) [391]
[3H]paroxetine (Inhibitor) (pKd 9.7),
[3H]citalopram (Inhibitor) (pKd 8.3)
Comments: [125I]RTI55 labels all three monoamine transporters (NET, DAT and SERT) with affinities between 0.5 and 5 nM. Cocaine is an inhibitor of all three transporters with pKi values between 6.5
and 7.2. Potential alternative splicing sites in non-coding regions of SERT and NET have been identified. A bacterial homologue of SERT shows allosteric modulation by selected anti-depressants [452].
GABA transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC6 neurotransmitter transporter family! GABA transporter subfamily
Overview: The activity of GABA-transporters located
predominantly upon neurones (GAT-1), glia (GAT-3) or both
(GAT-2, BGT-1) serves to terminate phasic GABA-ergic
transmission, maintain low ambient extracellular concentrations
of GABA, and recycle GABA for reuse by neurones. Nonetheless,
ambient concentrations of GABA are sufficient to sustain tonic
inhibition mediated by high affinity GABAA receptors in certain
neuronal populations [442]. GAT1 is the predominant GABA
transporter in the brain and occurs primarily upon the terminals
of presynaptic neurones and to a much lesser extent upon distal
astocytic processes that are in proximity to axons terminals.
GAT3 resides predominantly on distal astrocytic terminals that
are close to the GABAergic synapse. By contrast, BGT1 occupies
an extrasynaptic location possibly along with GAT2 which has
limited expression in the brain [329]. TauT is a high affinity
taurine transporter involved in osmotic balance that occurs in
the brain and non-neuronal tissues, such as the kidney, brush
border membrane of the intestine and blood brain barrier [83,
219]. CT1, which transports creatine, has a ubiquitous
expression pattern, often co-localizing with creatine kinase [83].
Nomenclature GAT1 GAT2 GAT3
Systematic nomenclature SLC6A1 SLC6A13 SLC6A11
HGNC, UniProt SLC6A1, P30531 SLC6A13, Q9NSD5 SLC6A11, P48066
Substrates nipecotic acid, guvacine nipecotic acid, guvacine guvacine, nipecotic acid
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(continued)
Nomenclature GAT1 GAT2 GAT3
Endogenous substrates GABA β-alanine, GABA β-alanine, GABA
Stoichiometry 2Na+: 1Cl-: 1GABA 2Na+: 1Cl-:1GABA  2Na+: 2 Cl-: 1GABA
Selective inhibitors NNC-711 (pIC50 7.4) [50], tiagabine (pIC50 7.2) [50], SKF89976A (pIC50
6.9) [117], CI-966 (pIC50 6.6) [50], (R/S) EF-1500 (pIC50 4.9–5.7),
(R)-EF-1520 (pIC50 5.1–5.4), LU32-176B (pIC50 5.4) [512] – Mouse,
(S)-EF-1520 (pIC50 3.6–3.9)
SNAP-5114 (pIC50 4.7) [49] – Rat –
Labelled ligands [3H]tiagabine (Inhibitor) – –
Nomenclature BGT1 TauT CT1
Systematic nomenclature SLC6A12 SLC6A6 SLC6A8
HGNC, UniProt SLC6A12, P48065 SLC6A6, P31641 SLC6A8, P48029
Endogenous substrates GABA, betaine β-alanine, taurine, GABA [9] creatine
Stoichiometry 3Na+: 1 (or 2) Cl-: 1GABA 2Na+: 1Cl-: 1 taurine Probably 2Na+: 1Cl-: 1 creatine
Selective inhibitors NNC052090 (pKi 5.9) [473] – Mouse,
(R/S) EF-1500 (pIC50 4.9), (R)-EF-1520
(pIC50 3.7–4.7), (S)-EF-1520 (pIC50
3.6–4.5), LU32-176B (pIC50 4) [512] –
Mouse
– –
Comments: The IC50 values for GAT1-4 reported in the table
reflect the range reported in the literature from studies of both
human and mouse transporters. There is a tendency towards
lower IC50 values for the human orthologue [295]. SNAP-5114 is
only weakly selective for GAT 2 and GAT3, with IC50 values in
the range 22 to >30 M at GAT1 and BGT1, whereas NNC052090
has at least an order of magnitude selectivity for BGT1 [see [93,
438] for reviews]. Compound (R)-4d [PMID: 16766089] is a
recently described compound that displays 20-fold selectivity for
GAT3 over GAT1 [174]. In addition to the inhibitors listed,
deramciclane is a moderately potent, though non-selective,
inhibitor of all cloned GABA transporters (IC50 = 26-46 M;
[116]). Diaryloxime and diarylvinyl ether derivatives of
nipecotic acid and guvacine that potently inhibit the uptake of
[3H]GABA into rat synaptosomes have been described [282].
Several derivatives of exo-THPO (e.g. N-methyl-exo-THPO and
N-acetyloxyethyl-exo-THPO) demonstrate selectivity as blockers
of astroglial, versus neuronal, uptake of GABA [see [93, 437] for
reviews]. GAT3 is inhibited by physiologically relevant
concentrations of Zn2+ [96]. Taut transports GABA, but with
low affinity, but CT1 does not, although it can be engineered to
do so by mutagenesis guided by LeuT as a structural template
[121]. Although inhibitors of creatine transport by CT1 (e.g.
β-guanidinopropionic acid, cyclocreatine,
guanidinoethane sulfonic acid) are known (e.g. [103]) they
insufficiently characterized to be included in the table.
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Glycine transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC6 neurotransmitter transporter family! Glycine transporter subfamily
Overview: Two gene products, GlyT1 and GlyT2, are known
that give rise to transporters that are predominantly located on
glia and neurones, respectively. Five variants of GlyT1 (a,b,c,d &
e) differing in their N- and C-termini are generated by alternative
promoter usage and splicing, and three splice variants of GlyT2
(a,b & c) have also been identified (see [36, 152, 194, 459] for
reviews). GlyT1 transporter isoforms expressed in glia
surrounding glutamatergic synapses regulate synaptic glycine
concentrations influencing NMDA receptor-mediated
neurotransmission [35, 175], but also are important, in early
neonatal life, for regulating glycine concentrations at inhibitory
glycinergic synapses [195]. Homozygous mice engineered to
totally lack GlyT1 exhibit severe respiratory and motor
deficiencies due to hyperactive glycinergic signalling and die
within the first postnatal day [195, 479]. Disruption of GlyT1
restricted to forebrain neurones is associated with enhancement
of EPSCs mediated by NMDA receptors and behaviours that are
suggestive of a promnesic action [532]. GlyT2 transporters
localised on the axons and boutons of glycinergic neurones
appear crucial for efficient transmitter loading of synaptic
vesicles but may not be essential for the termination of
inhibitory neurotransmission [196, 415]. Mice in which GlyT2
has been deleted develop a fatal hyperekplexia phenotype during
the second postnatal week [196] and mutations in the human
gene encoding GlyT2 (SLC6A5) have been identified in patients
with hyperekplexia (reviewed by [221]). ATB0+ (SLCA14) is a
transporter for numerous dipolar and cationic amino acids and
thus has a much broader substrate specificity than the glycine
transporters alongside which it is grouped on the basis of
structural similarity [83]. ATB0+ is expressed in various
peripheral tissues [83]. By contrast PROT (SLC6A7), which is
expressed only in brain in association with a subset of excitatory
nerve terminals, shows specificity for the transport of L-proline.
Nomenclature GlyT1 GlyT2 ATB0,+ PROT
Systematic nomenclature SLC6A9 SLC6A5 SLC6A14 SLC6A7
HGNC, UniProt SLC6A9, P48067 SLC6A5, Q9Y345 SLC6A14, Q9UN76 SLC6A7, Q99884
Endogenous substrates – – L-isoleucine > L-leucine,
L-methionine> L-phenylalanine
> L-tryptophan > L-valine >
L-serine [453]
–
Substrates – – BCH, zwitterionic or cationic
NOS inhibitors [224],
1-methyltryptophan [270],
valganciclovir [488]
–
Endogenous substrates sarcosine, glycine glycine β-alanine [8, 9] L-proline
Stoichiometry 2 Na+: 1 Cl-: 1 glycine 3 Na+: 1 Cl-: 1 glycine 2-3 Na+: 1 Cl-: 1 amino acid
[453]
Probably 2 Na+: 1 Cl-: 1
L-proline
Inhibitors – bitopertin (pEC50 <4.5) [385] – –
Selective inhibitors (R)-NFPS (pIC50 8.5–9.1), SSR-103800
(pIC50 8.7) [54],
N-methyl-SSR504734 (pIC50 8.6),
LY2365109 (pIC50 7.8), GSK931145
(pIC50 7.6), bitopertin (pEC50 7.5)
[385]
Org 25543 (pIC50 7.8) [76],
ALX 1393, ALX 1405
α-methyl-D,L-tryptophan (pIC50
3.6) [270] compound 58 [PMID: 25037917]
(pIC50 7.7) [553], LP-403812
(pIC50 7) [535]
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(continued)
Nomenclature GlyT1 GlyT2 ATB0,+ PROT
Labelled ligands [3H](R)-NPTS (Binding) (pKd 9) [323],
[3H]GSK931145 (Binding) (pKd 8.8)
[229], [35S]ACPPB (Binding) (pKd
8.7) [540], [3H]SB-733993 (Binding)
(pKd 8.7) [229],
[3H]N-methyl-SSR504734 (pKd
8.1–8.5), [3H]NFPS (pKd 7.7–8.2)
– – –
Comments – N-Oleoyl-L-carnitine (0.3M,
[71]) and and
N-arachidonoylglycine (IC50
5-8 M, [513]) have been
described as potential
endogenous selective GlyT2
inhibitors
– –
Comments: sarcosine is a selective transportable inhibitor of
GlyT1 and also a weak agonist at the glycine binding site of the
NMDA receptor [544], but has no effect on GlyT2. This difference
has been attributed to a single glycine residue in TM6 (serine
residue in GlyT2) [493]. Inhibition of GLYT1 by the sarcosine
derivatives NFPS, NPTS and Org 24598 is non-competitive [331,
341]. IC50 values for Org 24598 reported in the literature vary,
most likely due to differences in assay conditions [58, 331]. The
tricyclic antidepressant amoxapine weakly inhibits GlyT2 (IC50
92 M) with approximately 10-fold selectivity over GlyT1 [366].
The endogenous lipids arachidonic acid and anandamide exert
opposing effects upon GlyT1a, inhibiting (IC50 2 M) and
potentiating (EC50 13 M) transport currents, respectively
[381]. N-arachidonyl-glycine, N-arachidonyl-γ-aminobutyric acid
and N-arachidonyl-D-alanine have been described as endogenous
non-competitive inhibitors of GlyT2a, but not GlyT1b [136, 253,
513]. Protons [20] and Zn2+ [257] act as non-competitive
inhibitors of GlyT1b, with IC50 values of 100 nM and 10 M
respectively, but neither ion affects GlyT2 (reviewed by [491]).
Glycine transport by GLYT1 is inhibited by Li+, whereas GLYT2
transport is stimulated (both in the presence of Na+) [392].
Neutral amino acid transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC6 neurotransmitter transporter family! Neutral amino acid transporter subfamily
Overview: Certain members of neutral amino acid transport family are expressed upon the apical surface of epithelial cells and are important for the absorption of amino acids from the duodenum,
jejunum and ileum and their reabsorption within the proximal tubule of the nephron (i.e. B0AT1 (SLC6A19), SLC6A17, SLC6A18, SLC6A20). Others may function as transporters for neurotransmitters
or their precursors (i.e. B0AT2, SLC6A17) [65].
Nomenclature B0AT1 B0AT2 B0AT3
Systematic nomenclature SLC6A19 SLC6A15 SLC6A18
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Nomenclature B0AT1 B0AT2 B0AT3
HGNC, UniProt SLC6A19, Q695T7 SLC6A15, Q9H2J7 SLC6A18, Q96N87
Endogenous substrates L-leucine, L-methionine, L-isoleucine,
L-valine > L-asparagine, L-phenylalanine,
L-alanine, L-serine > L-threonine, glycine,
L-proline [64]
L-proline > L-alanine, L-valine,
L-methionine, L-leucine > L-isoleucine,
L-threonine, L-asparagine, L-serine,
L-phenylalanine > glycine [64]
L-alanine, glycine > L-methionine,
L-phenylalanine, L-leucine, L-histidine,
L-glutamine [494]
Stoichiometry 1 Na+: 1 amino acid [70] 1 Na+: 1 amino acid [62] Na+- and Cl- -dependent transport [450]
Inhibitors nimesulide (pIC50 4.6) [387] – Rat – –
Selective inhibitors – loratadine (pIC50 5.4) [102] –
Comments Mutations in B0AT1 are associated with
Hartnup disorder
– –
Nomenclature NTT5 NTT4 SIT1
Systematic nomenclature SLC6A16 SLC6A17 SLC6A20
HGNC, UniProt SLC6A16, Q9GZN6 SLC6A17, Q9H1V8 SLC6A20, Q9NP91
Endogenous substrates – L-leucine, L-methionine, L-proline > L-cysteine, L-alanine, L-glutamine, L-serine >
L-histidine, glycine [537]
–
Endogenous substrates – – L-proline
Stoichiometry – Na+-dependent, Cl--independent transport [537] 2 Na+: 1 Cl-: 1 imino acid [60]
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SLC8 family of sodium/calcium exchangers
Transporters! SLC superfamily of solute carriers! SLC8 family of sodium/calcium exchangers
Overview: The sodium/calcium exchangers (NCX) use the
extracellular sodium concentration to facilitate the extrusion of
calcium out of the cell. Alongside the plasma membrane
Ca2+-ATPase (PMCA) and sarcoplasmic/endoplasmic reticulum
Ca2+-ATPase (SERCA), as well as the sodium/potassium/calcium
exchangers (NKCX, SLC24 family), NCX allow recovery of
intracellular calcium back to basal levels after cellular
stimulation. When intracellular sodium ion levels rise, for
example, following depolarisation, these transporters can operate
in the reverse direction to allow calcium influx and sodium
efflux, as an electrogenic mechanism. Structural modelling
suggests the presence of 9 TM segments, with a large intracellular
loop between the fifth and sixth TM segments.
Nomenclature Sodium/calcium exchanger 1 Sodium/calcium exchanger 2 Sodium/calcium exchanger 3
Systematic nomenclature SLC8A1 SLC8A2 SLC8A3
Common abreviation NCX1 NCX2 NCX3
HGNC, UniProt SLC8A1, P32418 SLC8A2, Q9UPR5 SLC8A3, P57103
Stoichiometry 3 Na+ (in) : 1 Ca2+ (out) or 4 Na+ (in) : 1 Ca2+ (out) [124]; Reverse mode 1 Ca2+
(in): 1 Na+ (out)
– –
Comments: Although subtype-selective inhibitors of NCX function are not widely available, 3,4-dichlorobenzamil and CBDMB act as non-selective NCX inhibitors, while SEA0400, KB-R7943, SN6, and
ORM-10103 [256] act to inhibit NCX function with varying degrees of selectivity. BED is a selective NCX3 inhibitor [439].
Further Reading
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SLC9 family of sodium/hydrogen exchangers
Transporters! SLC superfamily of solute carriers! SLC9 family of sodium/hydrogen exchangers
Overview: Sodium/hydrogen exchangers or sodium/proton
antiports are a family of transporters that maintain cellular pH
by utilising the sodium gradient across the plasma membrane to
extrude protons produced by metabolism, in a stoichiometry of 1
Na+ (in) : 1 H+ (out). Several isoforms, NHE6, NHE7, NHE8 and
NHE9 appear to locate on intracellular membranes [351, 357,
365]. Li+ and NH4
+, but not K+, ions may also be transported by
some isoforms. Modelling of the topology of these transporters
indicates 12 TM regions with an extended intracellular
C-terminus containing multiple regulatory sites.
NHE1 is considered to be a ubiquitously-expressed
‘housekeeping’ transporter. NHE3 is highly expressed in the
intestine and kidneys and regulate sodium movements in those
tissues. NHE10 is present in sperm [504] and osteoclasts [307];
gene disruption results in infertile male mice [504].
Comments: Analogues of the non-selective cation transport inhibitor amiloride appear to inhibit NHE function through competitive inhibition of the extracellular Na+ binding site. The more selective
amiloride analogues MPA and ethylisopropylamiloride exhibit a rank order of affinity of inhibition of NHE1 > NHE2 > NHE3 [100, 480, 481].
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SLC10 family of sodium-bile acid co-transporters
Transporters! SLC superfamily of solute carriers! SLC10 family of sodium-bile acid co-transporters
Overview: The SLC10 family transport bile acids, sulphated
solutes, and other xenobiotics in a sodium-dependent manner.
The founding members, SLC10A1 (NTCP) and SLC10A2 (ASBT)
function, along with members of the ABC transporter family
(MDR1/ABCB1, BSEP/ABCB11 and MRP2/ABCC2) and the
organic solute transporter obligate heterodimer OSTα:OSTβ
(SLC51), to maintain the enterohepatic circulation of bile acids
[110, 281]. SLC10A6 (SOAT) functions as a sodium-dependent
transporter of sulphated solutes included sulfphated steroids and
bile acids [187, 189]. Transport function has not yet been
demonstrated for the 4 remaining members of the SLC10 family,
SLC10A3 (P3), SLC10A4 (P4), SLC10A5 (P5), and SLC10A7 (P7),
and the identity of their endogenous substrates remain unknown
[160, 189, 193, 500]. Members of the SLC10 family are predicted
to have seven transmembrane domains with an extracellular
N-terminus and cytoplasmic C-terminus [29, 215].
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Nomenclature Sodium/bile acid and sulphated solute Sodium/bile acid and sulphated solute Sodium/bile acid and sulphated solute
cotransporter 1 cotransporter 2 cotransporter 6
Systematic nomenclature SLC10A1 SLC10A2 SLC10A6
Common abreviation NTCP ASBT SOAT
HGNC, UniProt SLC10A1, Q14973 SLC10A2, Q12908 SLC10A6, Q3KNW5
Substrates tauroursodeoxycholic acid, taurocholic acid,
taurochenodeoxycholic acid > glycocholic acid >
cholic acid [336]
glycodeoxycholic acid >
glycoursodeoxycholic acid,
glycochenodeoxycholic acid >
taurocholic acid > cholic acid [101]
–
Substrates – – pregnenolone sulphate [187],
estrone-3-sulphate,
dehydroepiandrosterone sulphate [189],
taurolithocholic acid-3-sulphate
Endogenous substrates triiodothyronine, dehydroepiandrosterone sulphate
[101, 160, 336], estrone-3-sulphate, iodothyronine
sulphates
– –
Stoichiometry 2 Na+: 1 bile acid [29, 187] >1 Na+: 1 bile acid [101, 509] –
Inhibitors (-)-propranolol (pIC50 8.2) [279], cyclosporin A (pIC50
6) [279], (+)-propranolol (pIC50 5.3) [279],
cyclosporin A (pKi 5.1) [125], irbesartan (pKi 4.9) [125]
SC-435 (pIC50 8.8) [38], 264W94 (pIC50 7.3)
[475, 522]
–
Labelled ligands – [3H]taurocholic acid [101] –
Comments chenodeoxycholyl-N-nitrobenzoxadiazol-lysine is a
fluorescent bile acid analogue used as a probe [188,
509].
– –
Comments: Heterologously expressed SLC10A4 [188] or SLC10A7 [193] failed to exhibit significant transport of taurocholic acid, pregnenolone sulphate, dehydroepiandrosterone sulphate or choline.
SLC10A4 has recently been suggested to associate with neuronal vesicles [68].
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SLC11 family of proton-coupled metal ion transporters
Transporters! SLC superfamily of solute carriers! SLC11 family of proton-coupled metal ion transporters
Overview: The family of proton-coupled metal ion transporters
are responsible for movements of divalent cations, particularly
ferrous and manganese ions, across the cell membrane
(SLC11A2/DMT1) and across endosomal (SLC11A2/DMT1) or
lysosomal/phagosomal membranes (SLC11A1/NRAMP1),
dependent on proton transport. Both proteins appear to have 12
TM regions and cytoplasmic N- and C- termini. NRAMP1 is
involved in antimicrobial action in macrophages, although its
precise mechanism is undefined. Facilitated diffusion of divalent
cations into phagosomes may increase intravesicular free radicals
to damage the pathogen. Alternatively, export of divalent cations
from the phagosome may deprive the pathogen of essential
enzyme cofactors. SLC11A1/DMT1 is more widely expressed and
appears to assist in divalent cation assimilation from the diet, as
well as in phagocytotic cells.
Nomenclature NRAMP1 DMT1
Systematic nomenclature SLC11A1 SLC11A2
HGNC, UniProt SLC11A1, P49279 SLC11A2, P49281
Endogenous substrates Fe2+, Mn2+ Cu2+, Co2+, Cd2+, Fe2+, Mn2+
Stoichiometry 1 H+ : 1 Fe2+ (out) or 1 Fe2+ (in) : 1 H+ (out) 1 H+ : 1 Fe2+ (out) [212]
Comments: Loss-of-function mutations in NRAMP1 are associated with increased susceptibility to microbial infection (OMIM: 607948). Loss-of-function mutations in DMT1 are associated with
microcytic anemia (OMIM: 206100).
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SLC12 family of cation-coupled chloride transporters
Transporters! SLC superfamily of solute carriers! SLC12 family of cation-coupled chloride transporters
Overview: The SLC12 family of chloride transporters contribute
to ion fluxes across a variety of tissues, particularly in the kidney
and choroid plexus of the brain. Within this family, further
subfamilies are identifiable: NKCC1, NKCC2 and NCC constitute
a group of therapeutically-relevant transporters, targets for loop
and thiazide diuretics. These 12 TM proteins exhibit cytoplasmic
termini and an extended extracellular loop at TM7/8 and are
kidney-specific (NKCC2 and NCC) or show a more widespread
distribution (NKCC1). A second family, the K-Cl co-transporters
are also 12 TM domain proteins with cytoplasmic termini, but
with an extended extracellular loop at TM 5/6. CCC6 exhibits
structural similarities with the K-Cl co-transporters, while CCC9
is divergent, with 11 TM domains and a cytoplasmic N-terminus
and extracellular C-terminus.
Nomenclature Kidney-specific Na-K-Cl symporter Basolateral Na-K-Cl symporter Na-Cl symporter K-Cl cotransporter 1
Systematic nomenclature SLC12A1 SLC12A2 SLC12A3 SLC12A4
Common abreviation NKCC2 NKCC1 NCC KCC1
HGNC, UniProt SLC12A1, Q13621 SLC12A2, P55011 SLC12A3, P55017 SLC12A4, Q9UP95
Stoichiometry 1 Na+ : 1 K+ : 2 Cl- (in) 1 Na+ : 1 K+ : 2 Cl- (in) 1 Na+ : 1 Cl- (in) 1 K+ : 1 Cl- (out)
Inhibitors bumetanide (pIC50 6.5) [220],
piretanide (pIC50 6) [220],
furosemide (pIC50 5.2) [220]
piretanide (pIC50 5.6) [220],
bumetanide (pIC50 5.6) [220],
furosemide (pIC50 5.1) [220]
chlorothiazide, cyclothiazide,
hydrochlorothiazide, metolazone
DIOA
Nomenclature K-Cl cotransporter 2 K-Cl cotransporter 3 K-Cl cotransporter 4 Cation-chloride cotransporter 9
Systematic nomenclature SLC12A5 SLC12A6 SLC12A7 SLC12A8
Common abreviation KCC2 KCC3 KCC4 CCC9
HGNC, UniProt SLC12A5, Q9H2X9 SLC12A6, Q9UHW9 SLC12A7, Q9Y666 SLC12A8, A0AV02
Substrates – – – L-glutamic acid, spermine,
L-aspartic acid, spermidine
Stoichiometry 1 K+ : 1 Cl- (out) 1 K+ : 1 Cl- (out) 1 K+ : 1 Cl- (out) Unknown
Inhibitors VU0240551 (pIC50 6.2) [114],
DIOA
DIOA DIOA –
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Comments: DIOA is able to differentiate KCC isoforms from NKCC and NCC transporters, but also inhibits CFTR [250].
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SLC13 family of sodium-dependent sulphate/carboxylate transporters
Transporters! SLC superfamily of solute carriers! SLC13 family of sodium-dependent sulphate/carboxylate transporters
Overview: Within the SLC13 family, two groups of transporters may be differentiated on the basis of the substrates transported: NaS1 and NaS2 convey sulphate, while NaC1-3 transport carboxylates.
NaS1 and NaS2 transporters are made up of 13 TM domains, with an intracellular N terminus and are electrogenic with physiological roles in the intestine, kidney and placenta. NaC1, NaC2 and NaC3
are made up of 11 TM domains with an intracellular N terminus and are electrogenic, with physiological roles in the kidney and liver.
Nomenclature Na+/sulfate Na+/dicarboxylate Na+/dicarboxylate Na+/sulfate Na+/citrate
cotransporter cotransporter 1 cotransporter 3 cotransporter cotransporter
Systematic
nomenclature
SLC13A1 SLC13A2 SLC13A3 SLC13A4 SLC13A5
Common abreviation NaS1 NaC1 NaC3 NaS2 NaC2
HGNC, UniProt SLC13A1, Q9BZW2 SLC13A2, Q13183 SLC13A3, Q8WWT9 SLC13A4, Q9UKG4 SLC13A5, Q86YT5
Endogenous substrates SeO4
2-, SO4
2-,
S2O3
2-
citric acid, succinic acid citric acid, succinic acid SO4
2- citric acid, pyruvic acid
Stoichiometry 3 Na+ : 1 SO4
2- (in) 3 Na+ : 1
dicarboxylate2- (in)
Unknown 3 Na+ : SO4
2- (in) Unknown
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SLC14 family of facilitative urea transporters
Transporters! SLC superfamily of solute carriers! SLC14 family of facilitative urea transporters
Overview: As a product of protein catabolism, urea is moved
around the body and through the kidneys for excretion.
Although there is experimental evidence for concentrative urea
transporters, these have not been defined at the molecular level.
The SLC14 family are facilitative transporters, allowing urea
movement down its concentration gradient. Multiple splice
variants of these transporters have been identified; for UT-A
transporters, in particular, there is evidence for cell-specific
expression of these variants with functional impact [455].
Topographical modelling suggests that the majority of the
variants of SLC14 transporters have 10 TM domains, with a
glycosylated extracellular loop at TM5/6, and intracellular C- and
N-termini. The UT-A1 splice variant, exceptionally, has 20 TM
domains, equivalent to a combination of the UT-A2 and UT-A3
splice variants.
Nomenclature Erythrocyte urea transporter Kidney urea transporter
Systematic nomenclature SLC14A1 SLC14A2
Common abreviation UT-B UT-A
HGNC, UniProt SLC14A1, Q13336 SLC14A2, Q15849
Substrates acetamide [546], acrylamide [546], methylurea [546] –
Endogenous substrates ammonium carbonate [546], urea [546], formamide [546] urea [328]
Stoichiometry Equilibrative Equilibrative
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SLC15 family of peptide transporters
Transporters! SLC superfamily of solute carriers! SLC15 family of peptide transporters
Overview: The SLC15 family of peptide transporters may be
divided on the basis of structural and functional differences into
two subfamilies: SLC15A1 (PepT1) and SLC15A2 (PepT2)
transport di- and tripeptides, but not amino acids, whereas
SLC15A3 (PHT2) and SLC15A4 (PHT1) transport L-histidine and
some di- and tripeptides [105]. The transporters are 12 TM
proteins with intracellular termini and an extended extracellular
loop at TM 9/10. The crystal structure of PepTSo (a prokaryote
homologue of PepT1 and PepT2 from Shewanella oneidensis)
confirms many of the predicted structural features of
mammalian PepT1 and PepT2 [360].
PHT1 has been suggested to be intracellular [410], while PHT2
protein is located on lysosomes in transfected cells [52, 230,
426]. PHT1 is hypothesised to mediate efflux of bacterial-derived
peptides into the cytosol perhaps in the colon where SLC15A4
mRNA expression is increased in inflammatory bowel disease
[305]. Transport via PHT1 may be important in immune
responses as both Toll-like receptor- and NOD1-mediated
responses are reduced in PHT1 knockout mice or mouse strains
expressing mutations in PHT1 [45, 430].
Nomenclature Peptide transporter 1 Peptide transporter 2 Peptide transporter 3 Peptide transporter 4
Systematic nomenclature SLC15A1 SLC15A2 SLC15A3 SLC15A4
Common abreviation PepT1 PepT2 PHT2 PHT1
HGNC, UniProt SLC15A1, P46059 SLC15A2, Q16348 SLC15A3, Q8IY34 SLC15A4, Q8N697
Substrates fMet-Leu-Phe [337], cefadroxil
[177], valacyclovir [178],
cyclacillin [177],
muramyl dipeptide [496]
cefadroxil [177], cyclacillin [177] – valacyclovir [37]
Endogenous substrates dipeptides [135],
5-aminolevulinic acid [135],
tripeptides [135]
dipeptides,
5-aminolevulinic acid, tripeptides
L-histidine, carnosine, dipeptides,
tripeptides
carnosine, L-histidine, dipeptides,
tripeptides
Stoichiometry 2 H+ : 1 zwitterionic peptide (in) 2 H+ : 1 zwitterionic peptide (in) Unknown Unknown
Inhibitors Lys[Z(NO2)]-Pro (pKi 5) [283],
4-AMBA [107]
Lys[Z(NO2)]-Lys[Z(NO2)] [40,
472], Lys[Z(NO2)]-Pro
– –
Labelled ligands [11C]GlySar, [14C]GlySar,
[3H]GlySar
[11C]GlySar, [14C]GlySar,
[3H]GlySar
[14C]histidine, [3H]histidine [14C]histidine (Binding) [528],
[3H]histidine
Comments: The PepT1 and PepT2 transporters are particularly promiscuous in the transport of dipeptides and tripeptides from the endogenous amino acids, as well as some D-amino acid containing
peptides. PepT1 has also been exploited to allow delivery of therapeutic pro-drugs, such as those for zidovudine (zidovudine) [218], sulpiride [508] and cytarabine [457].
D-Ala-Lys-AMCA has been used as a fluorescent probe to identify transport via both PepT1 and PepT2 [416] .
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SLC16 family of monocarboxylate transporters
Transporters! SLC superfamily of solute carriers! SLC16 family of monocarboxylate transporters
Overview: Members of the SLC16 family may be divided into subfamilies on the basis of substrate selectivities, particularly lactate (e.g. L-lactic acid), pyruvic acid and ketone bodies, as well as aromatic
amino acids. Topology modelling suggests 12 TM domains, with intracellular termini and an extended loop at TM 6/7.
The proton-coupled monocarboxylate transporters (monocarboxylate transporters 1, 4, 2 and 3) allow transport of the products of cellular metabolism, principally lactate (e.g. L-lactic acid) and
pyruvic acid.
Nomenclature Monocarboxylate transporter 1 Monocarboxylate transporter 2 Monocarboxylate transporter 3 Monocarboxylate transporter 4
Systematic nomenclature SLC16A1 SLC16A7 SLC16A8 SLC16A3
Common abreviation MCT1 MCT2 MCT3 MCT4
HGNC, UniProt SLC16A1, P53985 SLC16A7, O60669 SLC16A8, O95907 SLC16A3, O15427
Substrates γ-hydroxybutyric acid [506] – – –
Endogenous substrates pyruvic acid, L-lactic acid,
β-D-hydroxybutyric acid
pyruvic acid, L-lactic acid L-lactic acid pyruvic acid, L-lactic acid
Stoichiometry 1 H+ : 1 monocarboxylate- (out) 1 H+ : 1 monocarboxylate- (out) 1 H+ : 1 monocarboxylate- (out) 1 H+ : 1 monocarboxylate- (out)
Nomenclature Monocarboxylate transporter 6 Monocarboxylate transporter 8 Monocarboxylate transporter 10
Systematic nomenclature SLC16A5 SLC16A2 SLC16A10
Common abreviation MCT6 MCT8 TAT1
HGNC, UniProt SLC16A5, O15375 SLC16A2, P36021 SLC16A10, Q8TF71
Endogenous substrates – triiodothyronine [169], T4 [169] L-tryptophan, L-phenylalanine, levodopa, L-tyrosine
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(continued)
Nomenclature Monocarboxylate transporter 6 Monocarboxylate transporter 8 Monocarboxylate transporter 10
Stoichiometry Unknown Unknown Unknown
Comments MCT6 has been reported to transport
bumetanide, but not short chain fatty acids [353].
– –
Comments: MCT1 and MCT2, but not MCT3 and MCT4, are inhibited by CHC, which also inhibits members of the mitochondrial transporter family, SLC25.
MCT5-MCT7, MCT9 and MCT11-14 are regarded as orphan transporters.
Further Reading
Bernal J et al. (2015) Thyroid hormone transporters-functions and clinical implications. Nat Rev Endocrinol 11: 406-417 [PMID:25942657]
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SLC17 phosphate and organic anion transporter family
Transporters! SLC superfamily of solute carriers! SLC17 phosphate and organic anion transporter family
Overview: The SLC17 family are sometimes referred to as Type I sodium-phosphate co-transporters, alongside Type II (SLC34 family) and Type III (SLC20 family) transporters. Within the SLC17 family,
however, further subgroups of organic anion transporters may be defined, allowing the accumulation of sialic acid in the endoplasmic reticulum and glutamate (e.g. L-glutamic acid) or nucleotides in
synaptic and secretory vesicles. Topology modelling suggests 12 TM domains.
Type I sodium-phosphate co-transporters
Transporters! SLC superfamily of solute carriers! SLC17 phosphate and organic anion transporter family! Type I sodium-phosphate co-transporters
Overview: Type I sodium-phosphate co-transporters are expressed in the kidney and intestine.
Nomenclature Sodium/phosphate Sodium/phosphate Sodium/phosphate Sodium/phosphate
cotransporter 1 cotransporter 3 cotransporter 4
cotransporter homolog
Systematic nomenclature SLC17A1 SLC17A2 SLC17A3 SLC17A4
Common abreviation NPT1 NPT3 NPT4 –
HGNC, UniProt SLC17A1, Q14916 SLC17A2, O00624 SLC17A3, O00476 SLC17A4, Q9Y2C5
Substrates probenecid [69], penicillin G [69], Cl- [240], organic acids [240],
uric acid [240], phosphate [240]
– – –
Stoichiometry Unknown Unknown Unknown Unknown
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Sialic acid transporter
Transporters! SLC superfamily of solute carriers! SLC17 phosphate and organic anion transporter family! Sialic acid transporter
Overview: The sialic acid transporter is expressed on both lysosomes and synaptic vesicles, where it appears to allow export of sialic acid and accumulation of acidic amino acids, respectively [349],
driven by proton gradients. In lysosomes, degradation of glycoproteins generates amino acids and sugar residues, which are metabolized further following export from the lysosome.
Nomenclature Sialin
Systematic nomenclature SLC17A5
Common abreviation AST
HGNC, UniProt SLC17A5, Q9NRA2
Endogenous substrates L-lactic acid, gluconate (out), L-glutamic acid (in) [349], glucuronic acid, L-aspartic acid [349], sialic acid
Stoichiometry 1 H+ : 1 sialic acid (out)
Comments: Loss-of-function mutations in sialin are associated with Salla disease (OMIM: 604369), an autosomal recessive neurodegenerative disorder associated with sialic acid storage disease [497].
Vesicular glutamate transporters (VGLUTs)
Transporters! SLC superfamily of solute carriers! SLC17 phosphate and organic anion transporter family! Vesicular glutamate transporters (VGLUTs)
Overview: Vesicular glutamate transporters (VGLUTs) allow accumulation of glutamate into synaptic vesicles, as well as secretory vesicles in endocrine tissues. The roles of VGLUTs in kidney and liver
are unclear. These transporters appear to utilize the proton gradient and also express a chloride conductance [33].
Nomenclature Vesicular glutamate transporter 1 Vesicular glutamate transporter 2 Vesicular glutamate transporter 3
Systematic nomenclature SLC17A7 SLC17A6 SLC17A8
Common abreviation VGLUT1 VGLUT2 VGLUT3
HGNC, UniProt SLC17A7, Q9P2U7 SLC17A6, Q9P2U8 SLC17A8, Q8NDX2
Endogenous substrates L-glutamic acid > D-glutamic acid L-glutamic acid > D-glutamic acid L-glutamic acid > D-glutamic acid
Stoichiometry Unknown Unknown Unknown
Comments: Endogenous ketoacids produced during fasting have been proposed to regulate VGLUT function through blocking chloride ion-mediated allosteric enhancement of transporter function
[258].
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Vesicular nucleotide transporter
Transporters! SLC superfamily of solute carriers! SLC17 phosphate and organic anion transporter family! Vesicular nucleotide transporter
Overview: The vesicular nucleotide transporter is the most recent member of the SLC17 family to have an assigned function. Uptake of ATP was independent of pH, but dependent on chloride ions
and membrane potential [431].
Nomenclature Vesicular nucleotide transporter
Systematic nomenclature SLC17A9
Common abreviation VNUT
HGNC, UniProt SLC17A9, Q9BYT1
Endogenous substrates guanosine 5’-diphosphate [431], guanosine-5’-triphosphate [431], ATP [431]
Stoichiometry Unknown
Comments: VGLUTs and VNUT can be inhibited by DIDS and evans blue dye.
Further Reading
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transporters. Nat. Rev. Neurosci. 12: 204-16 [PMID:21415847]
Marks J et al. (2010) Phosphate homeostasis and the renal-gastrointestinal axis. Am. J. Physiol. Renal
Physiol. 299: F285-96 [PMID:20534868]
Miyamoto K et al. (2011) Sodium-dependent phosphate cotransporters: lessons from gene
knockout and mutation studies. J Pharm Sci 100: 3719-30 [PMID:21567407]
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SLC18 family of vesicular amine transporters
Transporters! SLC superfamily of solute carriers! SLC18 family of vesicular amine transporters
Overview: The vesicular amine transporters (VATs) are putative
12 TM domain proteins that function to transport singly
positively charged amine neurotransmitters and hormones from
the cytoplasm and concentrate them within secretory vesicles.
They function as amine/proton antiporters driven by secondary
active transport utilizing the proton gradient established by a
multi-subunit vacuolar ATPase that acidifies secretory vesicles
(reviewed by [139]). The vesicular acetylcholine transporter
(VAChT; [148]) localizes to cholinergic neurons, but
non-neuronal expression has also been claimed [434]. Vesicular
monoamine transporter 1 (VMAT1, [146]) is mainly expressed in
peripheral neuroendocrine cells, but most likely not in the CNS,
whereas VMAT2 [147] distributes between both central and
peripheral sympathetic monoaminergic neurones [140].
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Nomenclature Vesicular monoamine Vesicular monoamine Vesicular acetylcholine solute carrier family 18,
transporter 1 transporter 2 transporter subfamily B, member 1
Systematic nomenclature SLC18A1 SLC18A2 SLC18A3 SLC18B1
Common abreviation VMAT1 VMAT2 VAChT –
HGNC, UniProt SLC18A1, P54219 SLC18A2, Q05940 SLC18A3, Q16572 Q6NT16
Substrates dexamfetamine (Ki 4.710
 5M)
[147], β-phenylethylamine (Ki
3.410 5M) [147], fenfluramine
(Ki 3.110
 6M) [147], MPP+ (Ki
6.910 5M) [147], MDMA (Ki
1.910 5M) [147]
β-phenylethylamine (Ki
3.710 6M) [147],
dexamfetamine (Ki 2.110
 6M)
[147], fenfluramine (Ki
5.110 6M) [147], MPP+ (Ki
8.910 6M) [147], MDMA (Ki
6.910 6M) [147]
TPP+ [56], ethidium [56],
N-methyl-pyridinium-2-aldoxime [56],
N-(4’-pentanonyl)-4-(4”-
dimethylamino-styryl)pyridinium [56]
–
Endogenous substrates histamine (Ki 4.610
 3M) [147],
5-hydroxytryptamine (Ki
1.410 6M) [147], dopamine (Ki
3.810 6M) [147],
(-)-noradrenaline (Ki
1.310 5M) [147], (-)-adrenaline
(Ki 5.510
 6M) [147]
histamine (Ki 1.410
 4M) [147],
dopamine (Ki 1.410
 6M) [147],
5-hydroxytryptamine (Ki
910 7M) [147],
(-)-noradrenaline (Ki
3.410 6M) [147], (-)-adrenaline
(Ki 1.910
 6M) [147]
acetylcholine (Ki 7.910
 4M) [57, 276],
choline (Ki 510
 4M) [57, 276]
–
Stoichiometry 1 amine (in): 2H+ (out) 1 amine (in): 2H+ (out) 1 amine (in): 2H+ (out) –
Inhibitors reserpine (pKi 7.5) [147],
ketanserin (pKi 5.8) [147],
tetrabenazine (pKi 4.7) [147]
reserpine (pKi 7.9) [147],
tetrabenazine (pKi 7) [147],
ketanserin (pKi 6.3) [147]
aminobenzovesamicol (pKi 10.9) [138],
vesamicol (pKi 8.7) [138]
–
Labelled ligands – [3H]TBZOH (Inhibitor) (pKd 8.2)
[495], [125I]iodovinyl-TBZ
(Inhibitor) (pKd 8.1) [293],
[11C]DTBZ (Inhibitor),
[125I]7-azido-8-iodoketanserine
(Inhibitor) [449]
[3H]vesamicol (pKd 8.4) [495],
[123I]iodobenzovesamicol
–
Comments: pKi values for endogenous and synthetic substrate inhibitors of human VMAT1 and VMAT2 are for inhibition of [
3H]5-HT uptake in transfected and permeabilised CV-1 cells as detailed by
[147]. In addition to the monoamines listed in the table, the trace amines tyramine and β-phenylethylamine are probable substrates for VMAT2 [140]. Probes listed in the table are those currently
employed; additional agents have been synthesized (e.g. [551]).
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SLC19 family of vitamin transporters
Transporters! SLC superfamily of solute carriers! SLC19 family of vitamin transporters
Overview: The B vitamins folic acid and thiamine are transported across the cell membrane, particularly in the intestine, kidneys and placenta, using pH differences as driving forces. Topological
modelling suggests the transporters have 12 TM domains.
Nomenclature Reduced folate transporter 1 Thiamine transporter 1 Thiamine transporter 2
Systematic nomenclature SLC19A1 SLC19A2 SLC19A3
Common abreviation FOLT ThTr1 ThTr2
HGNC, UniProt SLC19A1, P41440 SLC19A2, O60779 SLC19A3, Q9BZV2
Substrates N5-formyltetrahydrofolate, folinic acid,
methotrexate, folic acid [389]
– –
Endogenous substrates Other tetrahydrofolate-cofactors, Organic
phosphates; in particular, adenine
nucleotides, tetrahydrofolic acid [389],
N5-methylfolate [389],
thiamine monophosphate [547]
thiamine thiamine
Stoichiometry Folate (in) : organic phosphate (out),
precise stoichiometry unknown
A facilitative carrier not known to be
coupled to an inorganic or organic ion
gradient
A facilitative carrier not known to be
coupled to an inorganic or organic ion
gradient
Labelled ligands [3H]folic acid [19], [3H]methotrexate [19] [3H]thiamine [134] [3H]thiamine [399]
Comments: Loss-of-function mutations in ThTr1 underlie thiamine-responsive megaloblastic anemia syndrome [119].
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SLC20 family of sodium-dependent phosphate transporters
Transporters! SLC superfamily of solute carriers! SLC20 family of sodium-dependent phosphate transporters
Overview: The SLC20 family is looked upon not only as ion transporters, but also as retroviral receptors. As ion transporters, they are sometimes referred to as Type III sodium-phosphate
co-transporters, alongside Type I (SLC17 family) and Type II (SLC34 family). PiTs are cell-surface transporters, composed of ten TM domains with extracellular C- and N-termini. PiT1 is a focus for
dietary phosphate and vitamin D regulation of parathyroid hormone secretion from the parathyroid gland. PiT2 appears to be involved in intestinal absorption of dietary phosphate.
Nomenclature Sodium-dependent phosphate transporter 1 Sodium-dependent phosphate transporter 2
Systematic nomenclature SLC20A1 SLC20A2
Common abreviation PiT1 PiT2
HGNC, UniProt SLC20A1, Q8WUM9 SLC20A2, Q08357
Substrates AsO4
3- [400], phosphate [400] phosphate [400]
Stoichiometry >1 Na+ : 1 HPO4
2- (in) >1 Na+ : 1 HPO4
2- (in)
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Biber J et al. (2013) Phosphate transporters and their function. Annu. Rev. Physiol. 75: 535-50
[PMID:23398154]
Forster IC et al. (2013) Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med.
34: 386-95 [PMID:23506879]
Marks J et al. (2010) Phosphate homeostasis and the renal-gastrointestinal axis. Am. J. Physiol. Renal
Physiol. 299: F285-96 [PMID:20534868]
Miyamoto K et al. (2011) Sodium-dependent phosphate cotransporters: lessons from gene
knockout and mutation studies. J Pharm Sci 100: 3719-30 [PMID:21567407]
Shobeiri N et al. (2013) Phosphate: an old bone molecule but new cardiovascular risk factor. Br J
Clin Pharmacol [PMID:23506202]
Searchable database: http://www.guidetopharmacology.org/index.jsp SLC20 family of sodium-dependent phosphate transporters 6159
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13355/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Transporters. British Journal of Pharmacology (2015) 172, 6110–6202
SLC22 family of organic cation and anion transporters
Transporters! SLC superfamily of solute carriers! SLC22 family of organic cation and anion transporters
Overview: The SLC22 family of transporters is mostly composed of non-selective transporters, which are expressed highly in liver, kidney and intestine, playing a major role in drug disposition. The
family may be divided into three subfamilies based on the nature of the substrate transported: organic cations (OCTs), organic anions (OATs) and organic zwiterrion/cations (OCTN). Membrane
topology is predicted to contain 12 TM domains with intracellular termini, and an extended extracellular loop at TM 1/2.
Further Reading
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Organic cation transporters (OCT)
Transporters! SLC superfamily of solute carriers! SLC22 family of organic cation and anion transporters! Organic cation transporters (OCT)
Overview: Organic cation transporters (OCT) are electrogenic, Na+-independent and reversible.
Nomenclature Organic cation transporter 1 Organic cation transporter 2 Organic cation transporter 3
Systematic nomenclature SLC22A1 SLC22A2 SLC22A3
Common abreviation OCT1 OCT2 OCT3
HGNC, UniProt SLC22A1, O15245 SLC22A2, O15244 SLC22A3, O75751
Substrates MPP+, tetraethylammonium, desipramine,
metformin, aciclovir
MPP+ [198], pancuronium [198],
tetraethylammonium [198], tubocurarine
[198]
MPP+, tetraethylammonium, quinidine
Endogenous substrates PGF2α, choline, PGE2,
5-hydroxytryptamine
PGE2 [280], dopamine [209], histamine
[209]
(-)-noradrenaline [550], dopamine [550],
5-hydroxytryptamine [550]
Stoichiometry Unknown Unknown Unknown
Comments: corticosterone and quinine are able to inhibit all three organic cation transporters.
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Organic zwitterions/cation transporters (OCTN)
Transporters! SLC superfamily of solute carriers! SLC22 family of organic cation and anion transporters! Organic zwitterions/cation transporters (OCTN)
Overview: Organic zwitterions/cation transporters (OCTN) function as organic cation uniporters, organic cation/proton exchangers or sodium/L-carnitine co-transporters.
Nomenclature Organic cation/carnitine transporter 1 Organic cation/carnitine transporter 2 Carnitine transporter 2
Systematic nomenclature SLC22A4 SLC22A5 SLC22A16
Common abreviation OCTN1 OCTN2 CT2
HGNC, UniProt SLC22A4, Q9H015 SLC22A5, O76082 SLC22A16, Q86VW1
Substrates verapamil, pyrilamine,
tetraethylammonium, MPP+
verapamil, tetraethylammonium, MPP+,
pyrilamine
–
Endogenous substrates L-carnitine L-carnitine, acetyl-L-carnitine L-carnitine
Stoichiometry Unknown Unknown Unknown
Further Reading
Pochini L et al. (2013) OCTN cation transporters in health and disease: role as drug targets and
assay development. J Biomol Screen 18: 851-67 [PMID:23771822]
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Organic anion transporters (OATs)
Transporters! SLC superfamily of solute carriers! SLC22 family of organic cation and anion transporters! Organic anion transporters (OATs)
Overview: Organic anion transporters (OATs) are non-selective transporters prominent in the kidney and intestine
Nomenclature Organic anion transporter 1 Organic anion transporter 2 Organic anion transporter 3
Systematic nomenclature SLC22A6 SLC22A7 SLC22A8
Common abreviation OAT1 OAT2 OAT3
HGNC, UniProt SLC22A6, Q4U2R8 SLC22A7, Q9Y694 SLC22A8, Q8TCC7
Substrates aminohippuric acid, non-steroidal
anti-inflammatory drugs
aminohippuric acid, PGE2, non-steroidal
anti-inflammatory drugs
estrone-3-sulphate [294],
aminohippuric acid [294], cimetidine
[294], ochratoxin A [294]
Stoichiometry Unknown Unknown Unknown
Inhibitors probenecid (Inhibition of urate transport by
human SCL22A6.) (pIC50 4.9) [239]
– –
Nomenclature Organic anion transporter 7 Organic anion transporter 5 Organic anion transporter 4
Systematic nomenclature SLC22A9 SLC22A10 SLC22A11
Common abreviation OAT4 OAT5 –
HGNC, UniProt SLC22A9, Q8IVM8 SLC22A10, Q63ZE4 SLC22A11, Q9NSA0
Substrates – ochratoxin A [534] dehydroepiandrosterone sulphate [77], estrone-3-sulphate [77], ochratoxin A [77]
Stoichiometry Unknown Unknown Unknown
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Urate transporter
Transporters! SLC superfamily of solute carriers! SLC22 family of organic cation and anion transporters! Urate transporter
Nomenclature Urate anion exchanger 1
Systematic nomenclature SLC22A12
Common abreviation URAT1
HGNC, UniProt SLC22A12, Q96S37
Endogenous substrates uric acid [145], orotic acid [145]
Stoichiometry Unknown
Selective inhibitors sufinpyrazone (pIC50 4) [536]
SLC23 family of ascorbic acid transporters
Transporters! SLC superfamily of solute carriers! SLC23 family of ascorbic acid transporters
Overview: Predicted to be 12 TM segment proteins, members of this family transport the reduced form of ascorbic acid (while the oxidized form may be handled by members of the SLC2 family
(GLUT1/SLC2A1, GLUT3/SLC2A3 and GLUT4/SLC2A4). Phloretin is considered a non-selective inhibitor of these transporters, with an affinity in the micromolar range.
Nomenclature Sodium-dependent vitamin C Sodium-dependent vitamin C Sodium-dependent vitamin C Sodium-dependent nucleobase
transporter 1 transporter 2 transporter 3 transporter
Systematic nomenclature SLC23A1 SLC23A2 SLC23A3 SLC23A4
Common abreviation SVCT1 SVCT2 SVCT3 SNBT1
HGNC, UniProt SLC23A1, Q9UHI7 SLC23A2, Q9UGH3 SLC23A3, Q6PIS1 SLC23A4P, –
Endogenous substrates L-ascorbic acid > D-ascorbic acid
> dehydroascorbic acid [483]
L-ascorbic acid > D-ascorbic acid
> dehydroascorbic acid [483]
– uracil > thymine > guanine,
hypoxanthine > xanthine,
uridine [526]
Substrates – – – 5-fluorouracil [526]
Stoichiometry 2 Na+: 1 ascorbic acid (in) [483] 2 Na+: 1 ascorbic acid (in) [483] – 1 Na+ : 1 uracil (in) [526]
Inhibitors phloretin (pKi 4.2) [483] – – –
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(continued)
Nomenclature Sodium-dependent vitamin C Sodium-dependent vitamin C Sodium-dependent vitamin C Sodium-dependent nucleobase
transporter 1 transporter 2 transporter 3 transporter
Labelled ligands [14C]ascorbic acid (Binding)
[326]
[14C]ascorbic acid – –
Comments – – SLC23A3 does not transport
ascorbic acid and remains an
orphan transporter.
SLC23A4/SNBT1 is found in
rodents and non-human
primates, but the sequence is
truncated in the human genome
and named as a pseudogene,
SLC23A4P
Further Reading
Bürzle M et al. (2013) The sodium-dependent ascorbic acid transporter family SLC23. Mol. Aspects
Med. 34: 436-54 [PMID:23506882]
May JM. (2011) The SLC23 family of ascorbate transporters: ensuring that you get and keep your
daily dose of vitamin C. Br. J. Pharmacol. 164: 1793-801 [PMID:21418192]
Savini I et al. (2008) SVCT1 and SVCT2: key proteins for vitamin C uptake. Amino Acids 34: 347-55
[PMID:17541511]
SLC24 family of sodium/potassium/calcium exchangers
Transporters! SLC superfamily of solute carriers! SLC24 family of sodium/potassium/calcium exchangers
Overview: The sodium/potassium/calcium exchange family of transporters utilize the extracellular sodium gradient to drive calcium and potassium co-transport out of the cell. As is the case for NCX
transporters (SLC8A family), NKCX transporters are thought to be bidirectional, with the possibility of calcium influx following depolarization of the plasma membrane. Topological modeling suggests
the presence of 10 TM domains, with a large intracellular loop between the fifth and sixth TM regions.
Nomenclature Sodium/potassium/calcium exchanger 1 Sodium/potassium/calcium exchanger 6
Systematic nomenclature SLC24A1 SLC24A6
Common abreviation NKCX1 NKCX6
HGNC, UniProt SLC24A1, O60721 SLC8B1, Q6J4K2
Stoichiometry 4Na+:(1Ca2+ + 1K+) –
Comments: NKCX6 has been proposed to be the sole member of a CAX Na+/Ca2+ exchanger family, which may be the mitochondrial transporter responsible for calcium accumulation from the
cytosol [441].
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Altimimi HF et al. (2007) Na+/Ca2+-K+ exchangers (NCKX): functional properties and
physiological roles. Channels (Austin) 1: 62-9 [PMID:18690016]
Schnetkamp PP. (2013) The SLC24 gene family of NaC/Ca2C-KC exchangers: from sight and smell to
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Schnetkamp PP et al. (2014) The SLC24 family of KC-dependent NaC-Ca2C exchangers:
structure-function relationships. Curr Top Membr 73: 263-87 [PMID:24745986]
Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2+) exchanger.
Biochem. Biophys. Res. Commun. 460: 50-2 [PMID:25998733]
SLC25 family of mitochondrial transporters
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters
Overview: Mitochondrial transporters are nuclear-encoded proteins, which convey solutes across the inner mitochondrial membrane. Topological modelling suggests homodimeric transporters, each
with six TM segments and termini in the cytosol.
Mitochondrial di- and tri-carboxylic acid transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters!Mitochondrial di- and tri-carboxylic acid transporter subfamily
Overview: Mitochondrial di- and tri-carboxylic acid transporters are grouped on the basis of commonality of substrates and include the citrate transporter which facilitates citric acid export from the
mitochondria to allow the generation of oxalacetic acid and acetyl CoA through the action of ATP:citrate lyase.
Nomenclature Mitochondrial citrate Mitochondrial dicarboxylate Mitochondrial oxoglutarate Mitochondrial oxodicarboxylate
transporter transporter carrier carrier
Systematic nomenclature SLC25A1 SLC25A10 SLC25A11 SLC25A21
Common abreviation CIC DIC OGC ODC
HGNC, UniProt SLC25A1, P53007 SLC25A10, Q9UBX3 SLC25A11, Q02978 SLC25A21, Q9BQT8
Substrates phosphoenolpyruvic acid,
malic acid, citric acid
SO4
2-, phosphate, S2O3
2-,
succinic acid, malic acid
α-ketoglutaric acid, malic acid α-ketoglutaric acid,
α-oxoadipic acid
Stoichiometry Malate2- (in) : H-citrate2- (out) PO3
4- (in) : malate2- (out) Malate2- (in) : oxoglutarate2-
(out)
Oxoadipate (in) : oxoglutarate
(out)
Inhibitors 1,2,3-benzenetricarboxylic acid – – –
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Mitochondrial amino acid transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters!Mitochondrial amino acid transporter subfamily
Overview: Mitochondrial amino acid transporters can be subdivided on the basis of their substrates. Mitochondrial ornithine transporters play a role in the urea cycle by exchanging cytosolic
ornithine (L-ornithine and D-ornithine) for mitochondrial citrulline (L-citrulline and D-citrulline) in equimolar amounts. Further members of the family include transporters of S-adenosylmethionine
and carnitine.
Nomenclature AGC1 AGC2 Mitochondrial glutamate Mitochondrial glutamate
carrier 2 carrier 1
Systematic nomenclature SLC25A12 SLC25A13 SLC25A18 SLC25A22
Common abreviation – – GC2 GC1
HGNC, UniProt SLC25A12, O75746 SLC25A13, Q9UJS0 SLC25A18, Q9H1K4 SLC25A22, Q9H936
Substrates L-glutamic acid,
2-amino-3-sulfinopropanoic acid,
L-aspartic acid
2-amino-3-sulfinopropanoic acid,
L-glutamic acid, L-aspartic acid
L-glutamic acid L-glutamic acid
Stoichiometry Aspartate : glutamate H+
(bidirectional)
Aspartate : glutamate H+
(bidirectional)
Glutamate : H+ (bidirectional) Glutamate : H+ (bidirectional)
Nomenclature Mitochondrial ornithine transporter 2 Mitochondrial ornithine transporter 1 Carnitine/acylcarnitine carrier
Systematic nomenclature SLC25A2 SLC25A15 SLC25A20
Common abreviation ORC2 ORC1 CAC
HGNC, UniProt SLC25A2, Q9BXI2 SLC25A15, Q9Y619 SLC25A20, O43772
Substrates L-citrulline [161], L-arginine [161], L-lysine
[161], D-lysine [161], D-arginine [161],
D-citrulline [161], D-ornithine [161],
L-ornithine [161], D-histidine [161],
L-histidine [161]
L-lysine [161], L-ornithine [161], L-citrulline
[161], L-arginine [161]
–
Stoichiometry 1 Ornithine (in) :1 citrulline : 1 H+ (out) 1 Ornithine (in) :1 citrulline : 1 H+ (out) –
Comments – – Exchanges cytosolic acylcarnitine for
mitochondrial carnitine
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Comments: Both ornithine transporters are inhibited by the polyamine spermine [162]. Loss-of-function mutations in these genes are associated with
hyperornithinemia-hyperammonemia-homocitrullinuria.
Mitochondrial phosphate transporters
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters!Mitochondrial phosphate transporters
Overview: Mitochondrial phosphate transporters allow the import of inorganic phosphate for ATP production.
Nomenclature Mitochondrial phosphate carrier
Systematic nomenclature SLC25A3
Common abreviation PHC
HGNC, UniProt SLC25A3, Q00325
Stoichiometry PO3
4- (in) : OH- (out) or PO3
4- : H+ (in)
Mitochondrial nucleotide transporter subfamily
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters!Mitochondrial nucleotide transporter subfamily
Overview: Mitochondrial nucleotide transporters, defined by structural similarlities, include the adenine nucleotide translocator family (SLC25A4, SLC25A5, SLC25A6 and SLC25A31), which under
conditions of aerobic metabolism, allow coupling between mitochondrial oxidative phosphorylation and cytosolic energy consumption by exchanging cytosolic adenosine diphosphate for
mitochondrial ATP. Further members of the mitochondrial nucleotide transporter subfamily convey diverse substrates including CoA, although not all members have had substrates identified.
Nomenclature
Mitochondrial adenine nucleotide Mitochondrial adenine nucleotide Mitochondrial adenine nucleotide Mitochondrial adenine nucleotide
translocator 1 translocator 2 translocator 3 translocator 4
Systematic nomenclature SLC25A4 SLC25A5 SLC25A6 SLC25A31
Common abreviation ANT1 ANT2 ANT3 ANT4
HGNC, UniProt SLC25A4, P12235 SLC25A5, P05141 SLC25A6, P12236 SLC25A31, Q9H0C2
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Nomenclature
Mitochondrial adenine nucleotide Mitochondrial adenine nucleotide Mitochondrial adenine nucleotide Mitochondrial adenine nucleotide
translocator 1 translocator 2 translocator 3 translocator 4
Stoichiometry ADP3- (in) : ATP4- (out) ADP3- (in) : ATP4- (out) ADP3- (in) : ATP4- (out) ADP3- (in) : ATP4- (out)
Inhibitors bongkrek acid,
carboxyatractyloside
– – –
Nomenclature Graves disease carrier Peroxisomal membrane protein Deoxynucleotide carrier 1 S-Adenosylmethionine carrier
Systematic nomenclature SLC25A16 SLC25A17 SLC25A19 SLC25A26
Common abreviation GDC PMP34 DNC SAMC1
HGNC, UniProt SLC25A16, P16260 SLC25A17, O43808 SLC25A19, Q9HC21 SLC25A26, Q70HW3
Substrates CoA and congeners adenosine diphosphate, ATP,
adenosine 5’-monophosphate
Nucleotide Diphosphates
(NDPs), Deoxynucleotide
Diphosphates (dNDPs),
Dideoxynucleotide Triphosphates
(ddNTPs), Deoxynucleotide
Triphosphates (dNTPs)
S-adenosyl methionine
Stoichiometry CoA (in) ATP (in) dNDP (in) : ATP (out) –
Nomenclature Mitochondrial phosphate carrier 1 Mitochondrial phosphate carrier 2 Mitochondrial phosphate carrier 3
Systematic nomenclature SLC25A24 SLC25A23 SLC25A25
Common abreviation APC1 APC2 APC3
HGNC, UniProt SLC25A24, Q6NUK1 SLC25A23, Q9BV35 SLC25A25, Q6KCM7
Mitochondrial uncoupling proteins
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters!Mitochondrial uncoupling proteins
Overview: Mitochondrial uncoupling proteins allow dissipation of the mitochondrial proton gradient associated with thermogenesis and regulation of radical formation.
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Nomenclature Uncoupling protein 1 Uncoupling protein 2 Uncoupling protein 3
Systematic nomenclature SLC25A7 SLC25A8 SLC25A9
Common abreviation UCP1 UCP2 UCP3
HGNC, UniProt UCP1, P25874 UCP2, P55851 UCP3, P55916
Stoichiometry H+ (in) H+ (in) H+ (in)
Nomenclature Uncoupling protein 4 Uncoupling protein 5 KMCP1
Systematic nomenclature SLC25A27 SLC25A14 SLC25A30
Common abreviation UCP4 UCP5 –
HGNC, UniProt SLC25A27, O95847 SLC25A14, O95258 SLC25A30, Q5SVS4
Stoichiometry H+ (in) H+ (in) –
Miscellaneous SLC25 mitochondrial transporters
Transporters! SLC superfamily of solute carriers! SLC25 family of mitochondrial transporters!Miscellaneous SLC25 mitochondrial transporters
Overview: Many of the transporters identified below have yet to be assigned functions and are currently regarded as orphans.
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SLC26 family of anion exchangers
Transporters! SLC superfamily of solute carriers! SLC26 family of anion exchangers
Overview: Along with the SLC4 family, the SLC26 family acts to allow movement of monovalent and divalent anions across cell membranes. The predicted topology is of 10-14 TM domains with
intracellular C- and N-termini, probably existing as dimers. Within the family, subgroups may be identified on the basis of functional differences, which appear to function as anion exchangers and
anion channels (SLC26A7 and SLC26A9).
Selective sulphate transporters
Transporters! SLC superfamily of solute carriers! SLC26 family of anion exchangers! Selective sulphate transporters
Nomenclature Sat-1 DTDST
Systematic nomenclature SLC26A1 SLC26A2
HGNC, UniProt SLC26A1, Q9H2B4 SLC26A2, P50443
Substrates SO4
2-, oxalate SO4
2-
Stoichiometry SO4
2- (in) : anion (out) 1 SO4
2- (in) : 2 Cl- (out)
Chloride/bicarbonate exchangers
Transporters! SLC superfamily of solute carriers! SLC26 family of anion exchangers! Chloride/bicarbonate exchangers
Nomenclature DRA Pendrin PAT-1
Systematic nomenclature SLC26A3 SLC26A4 SLC26A6
HGNC, UniProt SLC26A3, P40879 SLC26A4, O43511 SLC26A6, Q9BXS9
Substrates Cl- formate, HCO3
-, OH-, I-, Cl- formate, oxalate, SO4
2-, OH-, Cl-, HCO3
-,
I-
Stoichiometry 2 Cl- (in) : 1 HCO3
- (out) or 2 Cl- (in) : 1
OH- (out)
Unknown 1 SO4
2- (in) : 2 HCO3
- (out) or 1 Cl- (in) :
2 HCO3
- (out)
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Anion channels
Transporters! SLC superfamily of solute carriers! SLC26 family of anion exchangers! Anion channels
Nomenclature SLC26A7 SLC26A9
HGNC, UniProt SLC26A7, Q8TE54 SLC26A9, Q7LBE3
Substrates NO3
-
 Cl- = Br- = I- > SO4
2- = L-glutamic acid I- > Br- > NO3
-
> Cl- > L-glutamic acid
Functional Characteristics Voltage- and time-independent current, linear I-V relationship [278] Voltage- and time-independent current, linear I-V relationship [127]
Comments – SLC26A9 has been suggested to operate in two additional modes as
a Cl--HCO3
- exchanger and as a Na+-anion cotransporter [79].
Other SLC26 anion exchangers
Transporters! SLC superfamily of solute carriers! SLC26 family of anion exchangers! Other SLC26 anion exchangers
Nomenclature Prestin
Systematic nomenclature SLC26A5
HGNC, UniProt SLC26A5, P58743
Substrates HCO3
- [347], Cl- [347]
Stoichiometry Unknown
Comments Prestin has been suggested to function as a molecular motor, rather than a transporter
Further Reading
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SLC27 family of fatty acid transporters
Transporters! SLC superfamily of solute carriers! SLC27 family of fatty acid transporters
Overview: Fatty acid transporter proteins (FATPs) are a family
(SLC27) of six transporters (FATP1-6). They have at least one, and
possibly six [312, 432], transmembrane segments, and are
predicted on the basis of structural similarities to form dimers.
SLC27 members have several structural domains: integral
membrane associated domain, peripheral membrane associated
domain, FATP signature, intracellular AMP binding motif,
dimerization domain, lipocalin motif, and an ER localization
domain (identified in FATP4 only) [153, 346, 373]. These
transporters are unusual in that they appear to express intrinsic
very long-chain acyl-CoA synthetase (EC 6.2.1.- , EC 6.2.1.7)
enzyme activity. Within the cell, these transporters may
associate with plasma and peroxisomal membranes. FATP1-4 and
-6 transport long- and very long-chain fatty acids, while FATP5
transports long-chain fatty acids as well as bile acids [344, 432].
Nomenclature Fatty acid transport protein 1 Fatty acid transport protein 2 Fatty acid transport protein 3
Systematic nomenclature SLC27A1 SLC27A2 SLC27A3
Common abreviation FATP1 FATP2 FATP3
HGNC, UniProt SLC27A1, Q6PCB7 SLC27A2, O14975 SLC27A3, Q5K4L6
Endogenous substrates palmitic acid > oleic acid > γ-linolenic acid > octanoic acid [190]; arachidonic acid
> palmitic acid > oleic acid > butyric acid [432]
– –
Nomenclature Fatty acid transport protein 4
Fatty acid transport protein 5
Fatty acid transport protein 6
Systematic
nomenclature
SLC27A4 SLC27A5 SLC27A6
Common abreviation FATP4 FATP5 FATP6
HGNC, UniProt SLC27A4, Q6P1M0 SLC27A5, Q9Y2P5 SLC27A6, Q9Y2P4
Endogenous substrates palmitic acid , oleic acid > γ-linolenic acid > octanoic acid [190]; palmitic acid
> oleic acid > butyric acid, γ-linolenic acid > arachidonic acid [454]
– palmitic acid > oleic acid >
γ-linolenic acid > octanoic acid [190]
Comments FATP4 is genetically linked to restrictive dermopathy. – –
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Comments: Although the stoichiometry of fatty acid transport
is unclear, it has been proposed to be facilitated by the coupling
of fatty acid transport to conjugation with coenzyme A to form
fatty acyl CoA esters. Small molecule inhibitors of FATP2 [314,
429] and FATP4 [43, 549], as well as bile acid inhibitors of FATP5
[549], have been described; analysis of the mechanism of action
of some of these inhibitors suggests that transport may be
selectively inhibited without altering enzymatic activity of the
FATP.
C1-BODIPY-C12 accumulation has been used as a non-selective
index of fatty acid transporter activity.
FATP2 has two variants: Variant 1 encodes the full-length
protein, while Variant 2 encodes a shorter isoform missing an
internal protein segment. FATP6 also has two variants: Variant 2
encodes the same protein as Variant 1 but has an additional
segment in the 5’ UTR.
Further Reading
Anderson CM et al. (2013) SLC27 fatty acid transport proteins. Mol. Aspects Med. 34: 516-28
[PMID:23506886]
Schwenk RW et al. (2010) Fatty acid transport across the cell membrane: regulation by fatty acid
transporters. Prostaglandins Leukot. Essent. Fatty Acids 82: 149-54 [PMID:20206486]
SLC28 and SLC29 families of nucleoside transporters
Transporters! SLC superfamily of solute carriers! SLC28 and SLC29 families of nucleoside transporters
Overview: Nucleoside transporters are divided into two families, the sodium-dependent, concentrative solute carrier family 28 (SLC28) and the equilibrative, solute carrier family 29 (SLC29). The
endogenous substrates are typically nucleosides, although some family members can also transport nucleobases and organic cations.
SLC28 family
Transporters! SLC superfamily of solute carriers! SLC28 and SLC29 families of nucleoside transporters! SLC28 family
Overview: SLC28 family membersappear to have 13 TM segments with cytoplasmic N-termini and extracellular C-termini, and function as concentrative nucleoside transporters.
Nomenclature Sodium/nucleoside cotransporter 1 Sodium/nucleoside cotransporter 2 Solute carrier family 28 member 3
Systematic nomenclature SLC28A1 SLC28A2 SLC28A3
Common abreviation CNT1 CNT2 CNT3
HGNC, UniProt SLC28A1, O00337 SLC28A2, O43868 SLC28A3, Q9HAS3
Substrates gemcitabine [90], zalcitabine, zidovudine cladribine [376], didanosine, vidarabine,
fludarabine [298], formycin B [298]
zalcitabine, formycin B, cladribine,
5-fluorouridine, floxuridine, didanosine,
zidovudine, zebularine, gemcitabine
Endogenous substrates adenosine, uridine, cytidine, thymidine adenosine, guanosine, inosine, thymidine adenosine, uridine, guanosine, thymidine,
inosine, cytidine
Stoichiometry 1 Na+ : 1 nucleoside (in) 1 Na+ : 1 nucleoside (in) 2 Na+ : 1 nucleoside (in)
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Comments: A further two Na+-dependent (stoichiometry 1 Na+ : 1 nucleoside (in)) nucleoside transporters have been defined on the basis of substrate and inhibitor selectivity: CNT4 (N4/cit, which
transports uridine, thymidine and guanosine) and CNT5 (N5/csg, which transports guanosine and adenosine, and may be inhibited by nitrobenzylmercaptopurine ribonucleoside).
SLC29 family
Transporters! SLC superfamily of solute carriers! SLC28 and SLC29 families of nucleoside transporters! SLC29 family
Overview: SLC29 family members appear to be composed of 11 TM segments with cytoplasmic N-termini and extracellular C-termini. ENT1, ENT2 and ENT4 are cell-surface transporters, while ENT3 is
intracellular, possibly lysosomal [27]. ENT1-3 are described as broad-spectrum equilibrative nucleoside transporters, while ENT4 is primarily a polyspecific organic cation transporter at neutral pH [231].
ENT4 transports adenosine only under acidotic conditions [31].
Nomenclature Equilibrative nucleoside Equilibrative nucleoside Equilibrative nucleoside Plasma membrane monoamine
transporter 1 transporter 2 transporter 3 transporter
Systematic nomenclature SLC29A1 SLC29A2 SLC29A3 SLC29A4
Common abreviation ENT1 ENT2 ENT3 PMAT
HGNC, UniProt SLC29A1, Q99808 SLC29A2, Q14542 SLC29A3, Q9BZD2 SLC29A4, Q7RTT9
Endogenous substrates in order
of increasing Km:
adenosine < inosine < uridine <
guanosine < cytidine < hypoxanthine <
adenine < thymine
– – –
Substrates tubercidin, cytarabine, ribavirin,
formycin B, cladribine,
2-chloroadenosine, gemcitabine,
didanosine, zalcitabine, pentostatin,
vidarabine, floxuridine
formycin B,
2-chloroadenosine,
cytarabine, tubercidin,
cladribine, gemcitabine,
vidarabine, zidovudine
zidovudine [27], zalcitabine
[27], didanosine [27],
fludarabine [27],
cordycepin [27], floxuridine
[27], cladribine [27],
tubercidin [27], zebularine
[27]
tetraethylammonium [144],
MPP+ [144]
Endogenous substrates adenine [529], cytidine [529], thymidine
[529], guanosine [529], thymine [529],
hypoxanthine [529], uridine [529],
adenosine [529], inosine [529]
adenosine, guanine,
thymine, uridine,
guanosine, hypoxanthine,
inosine, thymidine,
cytosine
adenosine [27], inosine
[27], uridine [27],
thymidine [27], guanosine
[27], adenine [27]
histamine [144], tyramine
[144], adenosine,
5-hydroxytryptamine [144],
dopamine [144]
Stoichiometry Equilibrative Equilibrative Equilibrative Equilibrative
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(continued)
Nomenclature Equilibrative nucleoside Equilibrative nucleoside Equilibrative nucleoside Plasma membrane monoamine
transporter 1 transporter 2 transporter 3 transporter
Inhibitors
nitrobenzylmercaptopurine ribonucleoside
(pKi 9.7), draflazine (pKi 9.6) [216],
KF24345 (pKi 9.4) [217], NBTGR (pKi
9.3), dilazep (pKi 9), dipyridamole (pKi
8.8) [217]
– – decynium 22 (pKi 7) [144],
rhodamine123 (pKi 6) [144],
dipyridamole (pKi 5.9) [503],
verapamil (pKi 4.7) [144],
fluoxetine (pKi 4.6) [144],
quinidine (pKi 4.6) [144],
quinine (pKi 4.6) [144],
desipramine (pKi 4.5) [144],
cimetidine (pKi <3.3) [144]
Labelled ligands
[3H]nitrobenzylmercaptopurine ribonucleoside
(pKd 9.3)
– – –
Comments ENT1 has 100-1000-fold lower affinity
for nucleobases as compared with
nucleosides [529].
The affinities of draflazine, dilazep,
KF24345 and dipyridamole at ENT1
transporters are species dependent,
exhibiting lower affinity at rat
transporters than at human transporters
[217, 458].
The loss of ENT1 activity in ENT1-null
mice has been associated with a
hypermineralization disorder similar to
human diffuse idiopathic skeletal
hyperostosis [507]. Lack of ENT1 also
results in the Augustine-null blood type
[106].
– Defects in SLC29A3 have
been implicated in
Histiocytosis-
lymphadenopathy plus
syndrome (OMIM:602782)
and lysosomal storage
diseases [233, 268].
–
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SLC30 zinc transporter family
Transporters! SLC superfamily of solute carriers! SLC30 zinc transporter family
Overview: Along with the SLC39 family, SLC30 transporters
regulate the movement of zinc ions around the cell. In
particular, these transporters remove zinc ions from the cytosol,
allowing accumulation into intracellular compartments or efflux
through the plasma membrane. ZnT1 is thought to be placed on
the plasma membrane extruding zinc, while ZnT3 is associated
with synaptic vesicles and ZnT4 and ZnT5 are linked with
secretory granules. Membrane topology predictions suggest a
multimeric assembly, potentially heteromultimeric [461], with
subunits having six TM domains, and both termini being
cytoplasmic. Dityrosine covalent linking has been suggested as a
mechanism for dimerisation, particularly for ZnT3 [427]. The
mechanism for zinc transport is unknown.
Comments: ZnT8/SLC30A8 is described as a type 1 diabetes susceptibility gene.
Zinc fluxes may be monitored through the use of radioisotopic Zn-65 or the fluorescent dye FluoZin 3.
Further Reading
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176-82 [PMID:20120011]
SLC31 family of copper transporters
Transporters! SLC superfamily of solute carriers! SLC31 family of copper transporters
Overview: SLC31 family members, alongside the Cu-ATPases are involved in the regulation of cellular copper levels. The CTR1 transporter is a cell-surface transporter to allow monovalent copper
accumulation into cells, while CTR2 appears to be a vacuolar/vesicular transporter [401]. Functional copper transporters appear to be trimeric with each subunit having three TM regions and an
extracellular N-terminus. CTR1 is considered to be a higher affinity copper transporter compared to CTR2. The stoichiometry of copper accumulation is unclear, but appears to be energy-independent
[304].
Nomenclature Copper transporter 1 Copper transporter 2
Systematic nomenclature SLC31A1 SLC31A2
Common abreviation CTR1 CTR2
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(continued)
Nomenclature Copper transporter 1 Copper transporter 2
HGNC, UniProt SLC31A1, O15431 SLC31A2, O15432
Substrates cisplatin [247] cisplatin [44]
Endogenous substrates copper [304] copper
Stoichiometry Unknown Unknown
Comments: Copper accumulation through CTR1 is sensitive to silver ions, but not divalent cations [304].
Further Reading
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implication in neurodegenerative diseases. Pharmacol. Ther. 133: 177-88 [PMID:22115751]
SLC32 vesicular inhibitory amino acid transporter
Transporters! SLC superfamily of solute carriers! SLC32 vesicular inhibitory amino acid transporter
Overview: The vesicular inhibitory amino acid transporter,
VIAAT (also termed the vesicular GABA transporter VGAT),
which is the sole representative of the SLC32 family, transports
GABA, or glycine, into synaptic vesicles [182, 183], and is a
member of the structurally-defined amino
acid-polyamine-organocation/APC clan composed of SLC32,
SLC36 and SLC38 transporter families (see [435]). VIAAT was
originally suggested to be composed of 10 TM segments with
cytoplasmic N- and C-termini [335]. However, an alternative
9TM structure with the N terminus facing the cytoplasm and the
C terminus residing in the synaptic vesicle lumen has
subsequently been reported [333]. VIAAT acts as an antiporter for
inhibitory amino acids and protons. The accumulation of GABA
and glycine within vesicles is driven by both the chemical (1pH)
and electrical (1 ) components of the proton electrochemical
gradient (1H+) established by a vacuolar H
+-ATPase [335].
However, one study, [259], presented evidence that VIAAT is
instead a Cl-/GABA co-transporter. VIAAT co-exists with VGLUT1
(SLC17A7), or VGLUT2 (SLC17A6), in the synaptic vesicles of
selected nerve terminals [155, 539]. VIAAT knock out mice die
between embryonic day 18.5 and birth [515]. In cultures of
spinal cord neurones established from earlier embryos, the
co-release of of GABA and glycine from synaptic vesicles is
drastically reduced, providing direct evidence for the role of
VIAAT in the sequestration of both transmitters [425, 515].
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Nomenclature Vesicular inhibitory amino acid transporter
Systematic nomenclature SLC32A1
Common abreviation VIAAT
HGNC, UniProt SLC32A1, Q9H598
Endogenous substrates β-alanine, γ-hydroxybutyric acid, GABA (Km 510
 3M) [335], glycine
Stoichiometry 1 amino acid (in): 1 H+ (out) [182] or 1 amino acid: 2Cl- (in) [259]
Inhibitors vigabatrin (pIC50 2.1) [335]
Further Reading
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Gasnier B. (2000) The loading of neurotransmitters into synaptic vesicles. Biochimie 82: 327-37
[PMID:10865121]
Gasnier B. (2004) The SLC32 transporter, a key protein for the synaptic release of inhibitory amino
acids. Pflugers Arch. 447: 756-9 [PMID:12750892]
Schiöth HB et al. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and
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SLC33 acetylCoA transporter
Transporters! SLC superfamily of solute carriers! SLC33 acetylCoA transporter
Overview: Acetylation of proteins is a post-translational modification mediated by specific acetyltransferases, using the donor acetyl CoA. SLC33A1/AT1 is a putative 11 TM transporter present on the
endoplasmic reticulum, expressed in all tissues, but particularly abundant in the pancreas [267], which imports cytosolic acetyl CoA into these intracellular organelles.
Nomenclature AcetylCoA transporter
Systematic nomenclature SLC33A1
Common abreviation ACATN1
HGNC, UniProt SLC33A1, O00400
Endogenous substrates acetyl CoA
Stoichiometry Unknown
Labelled ligands [14C]acetylCoA (Binding)
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Comments: In heterologous expression studies, acetyl CoA transport through AT1 was inhibited by coenzyme A, but not acetic acid, ATP or UDP-galactose [255]. A loss-of-function mutation in
ACATN1/SLC33A1 has been associated with spastic paraplegia (SPG42, [317]), although this observation could not be replicated in a subsequent study [436].
Further Reading
Hirabayashi Y et al. (2004) The acetyl-CoA transporter family SLC33. Pflugers Arch. 447: 760-2
[PMID:12739170]
Hirabayashi Y et al. (2013) The acetyl-CoA transporter family SLC33. Mol. Aspects Med. 34: 586-9
[PMID:23506891]
SLC34 family of sodium phosphate co-transporters
Transporters! SLC superfamily of solute carriers! SLC34 family of sodium phosphate co-transporters
Overview: The SLC34 family are sometimes referred to as Type II sodium-phosphate co-transporters, alongside Type I (SLC17 family) and Type III (SLC20 family) transporters. Topological modelling
suggests eight TM domains with C- and N- termini in the cytoplasm, and a re-entrant loop at TM7/8. SLC34 family members are expressed on the apical surfaces of epithelia in the intestine and kidneys
to regulate body phosphate levels, principally NaPi-IIa and NaPi-IIb, respectively. NaPi-IIa and NaPi-IIb are electrogenic, while NaPiIIc is electroneutral [10].
Nomenclature Sodium phosphate 1 Sodium phosphate 2 Sodium phosphate 3
Systematic nomenclature SLC34A1 SLC34A2 SLC34A3
Common abreviation NaPi-IIa NaPi-IIb NaPi-IIc
HGNC, UniProt SLC34A1, Q06495 SLC34A2, O95436 SLC34A3, Q8N130
Stoichiometry 3 Na+ : 1 HPO4
2- (in) [168] 3 Na+ : 1 HPO4
2- (in) [10] 2 Na+ : 1 HPO4
2- (in) [10]
Antibodies – lifastuzumab vedotin (Binding) [115] –
Comments: These transporters can be inhibited by foscarnet, in contrast to type III sodium-phosphate cotransporters, the SLC20 family.
Further Reading
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[PMID:23398154]
Forster IC et al. (2013) Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med.
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Clin Pharmacol [PMID:23506202]
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SLC35 family of nucleotide sugar transporters
Transporters! SLC superfamily of solute carriers! SLC35 family of nucleotide sugar transporters
Overview: Glycoprotein formation in the Golgi and endoplasmic reticulum relies on the accumulation of nucleotide-conjugated sugars via the SLC35 family of transporters. These transporters have a
predicted topology of 10 TM domains, with cytoplasmic termini, and function as exchangers, swopping nucleoside monophosphates for the corresponding nucleoside diphosphate conjugated sugar.
Five subfamilies of transporters have been identified on the basis of sequence similarity, namely SLC35A1, SLC35A2, SLC35A3, SLC35A4 and SLC35A5; SLC35B1, SLC35B2, SLC35B3 and SLC35B4;
SLC35C1 and SLC35C2; SLC35D1, SL35D1, SLC35D2 and SLC35D3, and the subfamily of orphan SLC35 transporters, SLC35E1-4 and SLC35F1-5.
Nomenclature CMP-sialic acid transporter UDP-galactose transporter UDP-N-acetylglucosamine PAPS transporter 1 PAPS transporter 2
transporter
Systematic
nomenclature
SLC35A1 SLC35A2 SLC35A3 SLC35B2 SLC35B3
HGNC, UniProt SLC35A1, P78382 SLC35A2, P78381 SLC35A3, Q9Y2D2 SLC35B2, Q8TB61 SLC35B3, Q9H1N7
Substrates CMP-sialic acid [243] UDP-galactose [245, 348],
UDP N-acetyl-glucosamine
[245, 348]
UDP N-acetyl-glucosamine
[246]
A3P5PS [262] A3P5PS [261]
Nomenclature YEA GDP-Fucose transporter UDP-glucuronic HFRC1
acid/UDP-N-acetylgalactosamine
dual transporter
Systematic nomenclature SLC35B4 SLC35C1 SLC35D1 SLC35D2
HGNC, UniProt SLC35B4, Q969S0 SLC35C1, Q96A29 SLC35D1, Q9NTN3 SLC35D2, Q76EJ3
Substrates UDP-xylose [18],
UDP N-acetyl-glucosamine [18]
GDP-fucose [325] UDP-N-acetylgalactosamine
[354], UDP-glucuronic acid [354]
UDP-N-acetylgalactosamine
[244]
Further Reading
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SLC36 family of proton-coupled amino acid transporters
Transporters! SLC superfamily of solute carriers! SLC36 family of proton-coupled amino acid transporters
Overview: The SLC36 family of proton-coupled amino acid transporters (or PAT) is highly expressed in the intestine and kidney, having roles in the disposition of amino acids [474]. PAT1 is found on
the gut epithelia luminal surface accumulating dietary amino acids, and additionally in lysosomal membranes where it likely functions as an efflux mechanism for amino acids produced during
intralysosomal proteolysis [4, 420]. PAT2 is found at the apical membrane of the kidney proximal tubule [66]. PAT1 and PAT2 are predicted to have 11 TM domains with intracellular N-termini [48, 420].
Nomenclature Proton-coupled Amino acid Proton-coupled Amino acid Proton-coupled Amino acid Proton-coupled Amino acid
Transporter 1 Transporter 2 Transporter 3 Transporter 4
Systematic nomenclature SLC36A1 SLC36A2 SLC36A3 SLC36A4
Common abreviation PAT1 PAT2 PAT3 PAT4
HGNC, UniProt SLC36A1, Q7Z2H8 SLC36A2, Q495M3 SLC36A3, Q495N2 SLC36A4, Q6YBV0
Substrates MeAIB [86], betaine, vigabatrin [1],
5-aminolevulinic acid,
β-guanidinopropionic acid, gaboxadol
[299], L-azetidine-2-carboxylate [274],
THPO [300]
MeAIB [87],
L-azetidine-2-carboxylate [274]
– –
Endogenous substrates GABA, L-alanine, β-alanine, taurine,
D-cysteine, D-serine, L-proline,
D-proline, trans-4-hydroxy-proline [338],
glycine [338], D-alanine, sarcosine
L-alanine, β-alanine, glycine,
sarcosine, L-proline,
trans-4-hydroxy-proline
– L-tryptophan [384],
L-proline [384]
Stoichiometry 1 H+ : 1 amino acid (in) 1 H+ : 1 amino acid (in) Unknown Unknown
Inhibitors 5-hydroxy-L-tryptophan (pKi 3) [339],
L-tryptophan (pKi 2.3) [339],
indole-3-propionic acid (pKi 2.3) [339],
5-hydroxytryptamine (pKi 2.2) [339]
5-hydroxy-L-tryptophan (pIC50 2.8)
[137], α-methyl-D,L-tryptophan
(pIC50 2.5) [137]
– –
Comments [3H] or [14C] labelled substrates as listed
above are used as probes
[3H] or [14C] labelled substrates as
listed above are used as probes
– –
Comments: Both PAT1 and PAT2 can also function as an electroneutral transport system for H+ and fatty acids including acetic acid, propanoic acid and butyric acid [164].
Loss-of-function mutations in PAT2 lead to iminoglycinuria and hyperglycinuria in man [65].
Further Reading
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SLC37 family of phosphosugar/phosphate exchangers
Transporters! SLC superfamily of solute carriers! SLC37 family of phosphosugar/phosphate exchangers
Overview: The family of sugar-phosphate exchangers pass particular phosphorylated sugars across intracellular membranes, exchanging for inorganic phosphate. Of the family of sugar phosphate
transporters, most information is available on SPX4, the glucose-6-phosphate transporter. This is a 10 TM domain protein with cytoplasmic termini and is associated with the endoplasmic reticulum,
with tissue-specific splice variation.
Nomenclature Glycerol-3-phosphate transporter Sugar phosphate exchanger 2 Glucose-6-phosphate transporter
Systematic
nomenclature
SLC37A1 SLC37A2 SLC37A4
Common
abreviation
SPX1 SPX2 SPX4
HGNC, UniProt SLC37A1, P57057 SLC37A2, Q8TED4 SLC37A4, O43826
Endogenous
substrates
glycerol 3-phosphate, glucose 6-phosphate glucose 6-phosphate glucose 6-phosphate
Stoichiometry Glucose 6-phosphate (in): phosphate (out) [379]. Glucose 6-phosphate (in): phosphate (out) [379]. Glucose 6-phosphate (in): phosphate (out) [84].
Comments – – Multiple polymorphisms have been described for the
SLC37A4 gene, some of which associate with a
glycogen storage disease [6].
Further Reading
Bartoloni L et al. (2004) The human sugar-phosphate/phosphate exchanger family SLC37. Pflugers
Arch. 447: 780-3 [PMID:12811562]
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SLC38 family of sodium-dependent neutral amino acid transporters
Transporters! SLC superfamily of solute carriers! SLC38 family of sodium-dependent neutral amino acid transporters
Overview: The SLC38 family of transporters appears to be responsible for the functionally-defined system A and system N mechanisms of amino acid transport and are mostly expressed in the CNS.
Two distinct subfamilies are identifiable within the SLC38 transporters. SNAT1, SNAT2 and SNAT4 appear to resemble system A transporters in accumulating neutral amino acids under the influence of
the sodium gradient. SNAT3 and SNAT5 appear to resemble system N transporters in utilizing proton co-transport to accumulate amino acids. The predicted membrane topology is of 11 TM domains
with an extracellular C-terminus and intracellular N-terminus [435].
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System A-like transporters
Transporters! SLC superfamily of solute carriers! SLC38 family of sodium-dependent neutral amino acid transporters! System A-like transporters
Nomenclature sodium-coupled neutral amino sodium-coupled neutral amino sodium-coupled neutral amino
acid transporter 1 acid transporter 2 acid transporter 4
Systematic nomenclature SLC38A1 SLC38A2 SLC38A4
Common abreviation SNAT1 SNAT2 SNAT4
HGNC, UniProt SLC38A1, Q9H2H9 SLC38A2, Q96QD8 SLC38A4, Q969I6
Substrates L-alanine > L-serine, L-glutamine,
L-asparagine, L-histidine, L-cysteine,
L-methionine > glycine, L-threonine,
L-proline, L-tyrosine, L-valine [5]
L-alanine, L-methionine > L-asparagine,
L-glutamine, L-serine, L-proline, glycine >
L-threonine, L-leucine, L-phenylalanine [223]
L-histidine > L-arginine, L-alanine, L-asparagine, L-lysine
> glycine, L-glutamine, L-serine, L-proline, L-leucine,
L-phenylalanine [222]
Substrates MeAIB MeAIB MeAIB
Stoichiometry 1 Na+ : 1 amino acid (in) [5] 1 Na+ : 1 amino acid (in) [223] 1 Na+ : 1 neutral amino acid (in) [222]
Labelled ligands [14C]alanine, [3H]alanine [14C]alanine, [3H]alanine [14C]alanine, [14C]glycine, [3H]alanine, [3H]glycine
Comments – – Transport of cationic amino acids by SNAT4 was
sodium-independent [222].
System N-like transporters
Transporters! SLC superfamily of solute carriers! SLC38 family of sodium-dependent neutral amino acid transporters! System N-like transporters
Nomenclature Sodium-coupled neutral amino acid transporter 3 Sodium-coupled neutral amino acid transporter 5
Systematic nomenclature SLC38A3 SLC38A5
Common abreviation SNAT3 SNAT5
HGNC, UniProt SLC38A3, Q99624 SLC38A5, Q8WUX1
Substrates L-histidine , L-glutamine > L-asparagine, L-alanine > L-glutamic acid
[157]
L-asparagine, L-serine, L-histidine, L-glutamine > glycine, L-alanine
[359]
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Nomenclature Sodium-coupled neutral amino acid transporter 3 Sodium-coupled neutral amino acid transporter 5
Substrates MeAIB MeAIB
Stoichiometry 1 Na+ : 1 amino acid (in) : 1 H+ (out) [59] 1 Na+ : 1 amino acid (in) : 1 H+ (out) [359]
Labelled ligands [14C]glutamine, [3H]glutamine [14C]histidine, [3H]histidine
Orphan SLC38 transporters
Transporters! SLC superfamily of solute carriers! SLC38 family of sodium-dependent neutral amino acid transporters! Orphan SLC38 transporters
Nomenclature Putative sodium-coupled neutral amino acid transporter 7
Systematic nomenclature SLC38A7
Common abreviation SNAT7
HGNC, UniProt SLC38A7, Q9NVC3
Comments SNAT7/SLC38A7 has been described to be a system N-like transporter allowing preferential accumulation of glutamine (e.g. L-glutamine),
histidine (e.g. L-histidine) and asparagine (e.g. L-asparagine) [237].
Further Reading
Bröer S. (2014) The SLC38 family of sodium-amino acid co-transporters. Pflugers Arch. 466: 155-72
[PMID:24193407]
Bröer S et al. (2011) The role of amino acid transporters in inherited and acquired diseases. Biochem.
J. 436: 193-211 [PMID:21568940]
Hägglund MG et al. (2011) Identification of SLC38A7 (SNAT7) protein as a glutamine transporter
expressed in neurons. J. Biol. Chem. 286: 20500-11 [PMID:21511949]
Mackenzie B et al. (2004) Sodium-coupled neutral amino acid (System N/A) transporters of the
SLC38 gene family. Pflugers Arch. 447: 784-95 [PMID:12845534]
Schiöth HB et al. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and
SLC38 and physiological, pathological and therapeutic aspects. Mol. Aspects Med. 34: 571-85
[PMID:23506890]
Sundberg BE et al. (2008) The evolutionary history and tissue mapping of amino acid transporters
belonging to solute carrier families SLC32, SLC36, and SLC38. J. Mol. Neurosci. 35: 179-93
[PMID:18418736]
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SLC39 family of metal ion transporters
Transporters! SLC superfamily of solute carriers! SLC39 family of metal ion transporters
Overview: Along with the SLC30 family, SLC39 family members regulate zinc movement in cells. SLC39 metal ion transporters accumulate zinc into the cytosol. Membrane topology modelling
suggests the presence of eight TM regions with both termini extracellular or in the lumen of intracellular organelles. The mechanism for zinc transport for many members is unknown but appears to
involve co-transport of bicarbonate ions [191, 321].
Nomenclature Zinc transporter 8 Zinc transporter 14
Systematic nomenclature SLC39A8 SLC39A14
Common abreviation ZIP8 ZIP14
HGNC, UniProt SLC39A8, Q9C0K1 SLC39A14, Q15043
Substrates Cd2+ [104, 321] Cd2+ [191], Mn2+ [191], Fe2+ [322]
Stoichiometry 1 Zn2+ (in) : 2 HCO3
- (in) [321] –
Comments: Zinc fluxes may be monitored through the use of radioisotopic Zn-65 or the fluorescent dye FluoZin 3.
The bicarbonate transport inhibitor DIDS has been reported to inhibit cation accumulation through ZIP14 [191].
Further Reading
Eide DJ. (2004) The SLC39 family of metal ion transporters. Pflugers Arch. 447: 796-800
[PMID:12748861]
Franz MC et al. (2013) Zinc transporters in prostate cancer. Mol. Aspects Med. 34: 735-41
[PMID:23506906]
Himeno S et al. (2009) The role of zinc transporters in cadmium and manganese transport in
mammalian cells. Biochimie 91: 1218-22 [PMID:19375483]
Jeong J et al. (2013) The SLC39 family of zinc transporters. Mol. Aspects Med. 34: 612-9
[PMID:23506894]
Kambe T et al. (2014) Current understanding of ZIP and ZnT zinc transporters in human health
and diseases. Cell. Mol. Life Sci. 71: 3281-95 [PMID:24710731]
Kambe T et al. (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in
Zinc Homeostasis and Metabolism. Physiol. Rev. 95: 749-784 [PMID:26084690]
Marger L et al. (2014) Zinc: an underappreciated modulatory factor of brain function. Biochem.
Pharmacol. 91: 426-35 [PMID:25130547]
Rungby J. (2010) Zinc, zinc transporters and diabetes. Diabetologia 53: 1549-51 [PMID:20490449]
Thévenod F. (2010) Catch me if you can! Novel aspects of cadmium transport in mammalian cells.
Biometals 23: 857-75 [PMID:20204475]
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SLC40 iron transporter
Transporters! SLC superfamily of solute carriers! SLC40 iron transporter
Overview: Alongside the SLC11 family of proton-coupled metal
transporters, ferroportin allows the accumulation of iron from
the diet. Whilst SLC11A2 functions on the apical membrane,
ferroportin acts on the basolateral side of the enterocyte, as well
as regulating macrophage and placental iron levels. The
predicted topology is of 12 TM domains, with intracellular
termini [407], with the functional transporter potentially a
dimeric arrangement [3, 111]. Ferroportin is essential for iron
homeostasis [126]. Ferroportin is expressed on the surface of cells
that store and transport iron, such as duodenal enterocytes,
hepatocytes, adipocytes and reticuloendothelial macrophages.
Levels of ferroportin are regulated by its association with
(binding to) hepcidin, a 25 amino acid hormone responsive to
circulating iron levels (amongst other signals). Hepcidin binding
targets ferroportin for internalisation and degradation, lowering
the levels of iron export to the blood. Novel therapeutic agents
which stabilise ferroportin or protect it from hepcidin-induced
degradation are being developed as anti-anemia agents.
Anti-ferroportin monoclonal antibodies are such an agent.
Nomenclature Ferroportin
Systematic nomenclature SLC40A1
Common abreviation IREG1
HGNC, UniProt SLC40A1, Q9NP59
Endogenous substrates Fe2+
Stoichiometry Unknown
Antibodies LY2928057 (Binding) [310]
Comments: Hepcidin (HAMP, P81172), cleaved into hepcidin-25 (HAMP, P81172) and hepcidin-20 (HAMP, P81173), is a small protein that increases upon inflammation, binds to ferroportin to
regulate its cellular distribution and degradation. Gene disruption in mice results in embryonic lethality [126], while loss-of-function mutations in man are associated with haemochromatosis [112].
Further Reading
McKie AT et al. (2004) The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1).
Pflugers Arch. 447: 801-6 [PMID:12836025]
Montalbetti N et al. (2013) Mammalian iron transporters: families SLC11 and SLC40. Mol. Aspects
Med. 34: 270-87 [PMID:23506870]
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SLC41 family of divalent cation transporters
Transporters! SLC superfamily of solute carriers! SLC41 family of divalent cation transporters
Overview: By analogy with bacterial orthologues, this family is probably magnesium transporters. The prokaryote orthologue, MgtE, is responsible for uptake of divalent cations, while the
heterologous expression studies of mammalian proteins suggest Mg2+ efflux [287], possibly as a result of co-expression of particular protein partners (see [421]). Topological modelling suggests 10 TM
domains with cytoplasmic C- and N- termini.
Nomenclature Solute carrier family 41 member 1 Solute carrier family 41 member 2
Systematic nomenclature SLC41A1 SLC41A2
Common abreviation MgtE –
HGNC, UniProt SLC41A1, Q8IVJ1 SLC41A2, Q96JW4
Substrates Co2+ [201], Cu2+ [201], Ba2+ [201], Cd2+ [201], Zn2+ [201],
Mg2+ [201], Sr2+ [201], Fe2+ [201]
Ba2+ [200], Mg2+ [200], Co2+ [200], Ni2+ [200], Mn2+ [200],
Fe2+ [200]
Stoichiometry Unknown Unknown
Further Reading
Moomaw AS et al. (2008) The unique nature of mg2+ channels. Physiology (Bethesda) 23: 275-85
[PMID:18927203]
Payandeh J et al. (2013) The structure and regulation of magnesium selective ion channels.
Biochim. Biophys. Acta [PMID:23954807]
Quamme GA. (2010) Molecular identification of ancient and modern mammalian magnesium
transporters. Am. J. Physiol., Cell Physiol. 298: C407-29 [PMID:19940067]
Sahni J et al. (2013) The SLC41 family of MgtE-like magnesium transporters. Mol. Aspects Med. 34:
620-8 [PMID:23506895]
Schweigel-Röntgen M et al. (2014) SLC41 transporters–molecular identification and functional role.
Curr Top Membr 73: 383-410 [PMID:24745990]
SLC42 family of Rhesus glycoprotein ammonium transporters
Transporters! SLC superfamily of solute carriers! SLC42 family of Rhesus glycoprotein ammonium transporters
Overview: Rhesus is commonly defined as a ‘factor’ that
determines, in part, blood type, and whether neonates suffer
from haemolytic disease of the newborn. These glycoprotein
antigens derive from two genes, RHCE (P18577) and RHD
(Q02161), expressed on the surface of erythrocytes. On
erythrocytes, RhAG associates with these antigens and functions
as an ammonium transporter. RhBG and RhBG are
non-erythroid related sequences associated with epithelia.
Topological modelling suggests the presence of 12TM with
cytoplasmic N- and C- termini. The majority of information on
these transporters derives from orthologues in yeast, plants and
bacteria. More recent evidence points to family members being
permeable to carbon dioxide, leading to the term gas channels.
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Nomenclature Ammonium transporter Rh type A Ammonium transporter Rh type B Ammonium transporter Rh type C
Systematic nomenclature SLC42A1 SLC42A2 SLC42A3
Common abreviation RhAG RhBG RhCG
HGNC, UniProt RHAG, Q02094 RHBG, Q9H310 RHCG, Q9UBD6
Substrates NH4
+ [510], NH3 [408], CO2 [143] – NH3 [552]
Stoichiometry Unknown Unknown Unknown
Labelled ligands [14C]methylamine (Binding) [228] – [14C]methylamine (Binding) [330] –
Mouse
Further Reading
Huang CH et al. (2010) The Rh protein family: gene evolution, membrane biology, and disease
association. Cell. Mol. Life Sci. 67: 1203-18 [PMID:19953292]
Nakhoul NL et al. (2004) Non-erythroid Rh glycoproteins: a putative new family of mammalian
ammonium transporters. Pflugers Arch. 447: 807-12 [PMID:12920597]
Nakhoul NL et al. (2013) Characteristics of mammalian Rh glycoproteins (SLC42 transporters) and
their role in acid-base transport. Mol. Aspects Med. 34: 629-37 [PMID:23506896]
Weiner ID et al. (2011) Role of NH3 and NH4+ transporters in renal acid-base transport. Am. J.
Physiol. Renal Physiol. 300: F11-23 [PMID:21048022]
Weiner ID et al. (2014) Ammonia transport in the kidney by Rhesus glycoproteins. Am. J. Physiol.
Renal Physiol. 306: F1107-20 [PMID:24647713]
SLC43 family of large neutral amino acid transporters
Transporters! SLC superfamily of solute carriers! SLC43 family of large neutral amino acid transporters
Overview: LAT3 (SLC43A1) and LAT4 (SLC43A2) are
transporters with system L amino acid transporter activity, along
with the structurally and functionally distinct transporters LAT1
and LAT2 that are members of the SLC7 family. LAT3 and LAT4
contain 12 putative TM domains with both N and C termini
located intracellularly. They transport neutral amino acids in a
manner independent of Na+ and Cl- and with two kinetic
components [22, 47]. LAT3/SLC43A1 is expressed in human
tissues at high levels in the pancreas, liver, skeletal muscle and
fetal liver [22] whereas LAT4/SLC43A2 is primarily expressed in
the placenta, kidney and peripheral blood leukocytes [47].
SLC43A3 is expressed in vascular endothelial cells [502] but
remains to be characterised.
Nomenclature L-type amino acid transporter 3 L-type amino acid transporter 4
Systematic nomenclature SLC43A1 SLC43A2
Common abreviation LAT3 LAT4
HGNC, UniProt SLC43A1, O75387 SLC43A2, Q8N370
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Nomenclature L-type amino acid transporter 3 L-type amino acid transporter 4
Substrates L-isoleucine [22], L-valinol [22], L-leucinol [22], L-phenylalaninol
[22], L-leucine [22], L-phenylalanine [22], L-valine [22],
L-methionine [22]
L-isoleucine, L-valinol, L-leucinol, L-leucine, L-phenylalanine,
L-valine, L-methionine
Stoichiometry Operates by facilitative diffusion Operates by facilitative diffusion
Comments: Covalent modification of LAT3 by N-ethylmaleimide inhibits its function [22] and at LAT4 inhibits the low-, but not high-affinity component of transport [47].
Further Reading
Bodoy S et al. (2013) The small SLC43 family: facilitator system l amino acid transporters and the orphan EEG1. Mol. Aspects Med. 34: 638-45 [PMID:23268354]
SLC44 choline transporter-like family
Transporters! SLC superfamily of solute carriers! SLC44 choline transporter-like family
Overview: Members of the choline transporter-like family are
encoded by five genes (CTL1-CTL5) with further diversity
occurring through alternative splicing of CTL1, 4 and 5 [477].
CTL family members are putative 10TM domain proteins with
extracellular termini that mediate Na+-independent transport of
choline with an affinity that is intermediate to that of the high
affinity choline transporter CHT1 (SLC5A7) and the low affinity
organic-cation transporters [OCT1 (SLC22A1) and OCT2
(SLC22A2)] [343]. CLT1 is expressed almost ubiquitously in
human tissues [514] and mediates choline transport across the
plasma and mitochondrial membranes [342]. Transport of
choline by CTL2, which in rodents is expressed as two isoforms
(CTL2P1 and CLTP2; [288]) in lung, colon, inner ear and spleen
and to a lesser extent in brain, tongue, liver, and kidney, has only
recently been demonstrated [288, 358]. CTL3-5 remain to be
characterized functionally.
Nomenclature Choline transporter-like 1
Systematic nomenclature SLC44A1
Common abreviation CTL1
HGNC, UniProt SLC44A1, Q8WWI5
Substrates choline
Stoichiometry Unknown: uptake enhanced in the absence of extracellular Na+, reduced by membrane depolarization, extracellular acidification and collapse of
plasma membrane H+ electrochemical gradient
Inhibitors hemicholinium-3 (pKi 3.5–4.5)
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Comments: Data tabulated are features observed for CLT1 endogenous to: rat astrocytes [242]; rat renal tubule epithelial cells [524]; human colon carcinoma cells [289]; human keratinocytes [486] and
human neuroblastoma cells [525]. Choline uptake by CLT1 is inhibited by numerous organic cations (e.g. [242, 524, 525]). In the guinea-pig, CTL2 is a target for antibody-induced hearing loss [355] and
in man, a polymorphism in CTL2 constitutes the human neutrophil alloantigen-3a (HNA-3a; [203]).
Further Reading
Inazu M. (2014) Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target
for cancer therapy. Biopharm Drug Dispos 35: 431-49 [PMID:24532461]
Lockman PR et al. (2002) The transport of choline. Drug Dev Ind Pharm 28: 749-71
[PMID:12236062]
Michel V et al. (2006) Choline transport for phospholipid synthesis. Exp. Biol. Med. (Maywood) 231:
490-504 [PMID:16636297]
Traiffort E et al. (2013) The choline transporter-like family SLC44: properties and roles in human
diseases. Mol. Aspects Med. 34: 646-54 [PMID:23506897]
SLC45 family of putative sugar transporters
Transporters! SLC superfamily of solute carriers! SLC45 family of putative sugar transporters
Overview: Members of the SLC45 family remain to be fully characterised. SLC45A1 was initially identified in the rat brain, particularly predominant in the hindbrain, as a proton-associated sugar
transport, induced by hypercapnia [447]. The protein is predicted to have 12TM domains, with intracellular termini. The SLC45A2 gene is thought to encode a transporter protein that mediates melanin
synthesis. Mutations in SLC45A2 are a cause of oculocutaneous albinism type 4 (e.g. [361]), and polymorphisms in this gene are associated with variations in skin and hair color (e.g. [202]).
Nomenclature Proton-associated sugar transporter A
Systematic nomenclature SLC45A1
HGNC, UniProt SLC45A1, Q9Y2W3
Substrates L-glucose [447], Galactose [447]
Stoichiometry Unknown; increased at acid pH [447].
Further Reading
Bartölke R et al. (2014) Proton-associated sucrose transport of mammalian solute carrier family 45:
an analysis in Saccharomyces cerevisiae. Biochem. J. 464: 193-201 [PMID:25164149]
Vitavska O et al. (2013) The SLC45 gene family of putative sugar transporters. Mol. Aspects Med. 34:
655-60 [PMID:23506898]
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SLC46 family of folate transporters
Transporters! SLC superfamily of solute carriers! SLC46 family of folate transporters
Overview: Based on the proptypical member of this family, PCFT, this family includes proton-driven transporters with 11 TM segments. SLC46A1 has been described to act as an intestinal
proton-coupled high-affinity folic acid transporter [393], with lower affinity for heme. Folic acid accumulation is independent of Na+ or K+ ion concentrations, but driven by extracellular protons with
an as yet undefined stoichiometry.
Nomenclature Proton-coupled folate transporter
Systematic nomenclature SLC46A1
Common abreviation PCFT
HGNC, UniProt SLC46A1, Q96NT5
Substrates folic acid (1.3M) > heme (>100 M) [356]
Substrates pemetrexed, N-formyltetrahydrofolate, methotrexate [393]
Endogenous substrates N5-methyltetrafolate [393]
Labelled ligands [3H]N5-methylfolate (Binding), [3H]folic acid, [3H]folinic acid (Binding), [3H]methotrexate, [3H]pemetrexed (Binding)
Comments Loss-of-function mutations in PCFT (SLC46A1) are the molecular basis for hereditary folate maladsorption [428].
Further Reading
Anderson CM et al. (2010) Hijacking solute carriers for proton-coupled drug transport. Physiology
(Bethesda) 25: 364-77 [PMID:21186281]
Desmoulin SK et al. (2012) The human proton-coupled folate transporter: Biology and therapeutic
applications to cancer. Cancer Biol. Ther. 13: 1355-73 [PMID:22954694]
Hou Z et al. (2014) Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr
Top Membr 73: 175-204 [PMID:24745983]
Matherly LH et al. (2014) The major facilitative folate transporters solute carrier 19A1 and solute
carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab. Dispos. 42:
632-49 [PMID:24396145]
Thwaites DT et al. (2007) H+-coupled nutrient, micronutrient and drug transporters in the
mammalian small intestine. Exp. Physiol. 92: 603-19 [PMID:17468205]
Wilson MR et al. (2015) Structural determinants of human proton-coupled folate transporter
oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at
transmembrane domains 3 and 6. Biochem. J. [PMID:25877470]
Zhao R et al. (2011) Mechanisms of membrane transport of folates into cells and across epithelia.
Annu. Rev. Nutr. 31: 177-201 [PMID:21568705]
Zhao R et al. (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3
and SLC46A1) and folate receptors. Mol. Aspects Med. 34: 373-85 [PMID:23506878]
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SLC47 family of multidrug and toxin extrusion transporters
Transporters! SLC superfamily of solute carriers! SLC47 family of multidrug and toxin extrusion transporters
Overview: These proton:organic cation exchangers are predicted to have 13 TM segments [545] and are suggested to be responsible for excretion of many drugs in the liver and kidneys.
Nomenclature Multidrug and toxin extrusion MATE2
Systematic nomenclature SLC47A1 SLC47A2
Common abreviation MATE1 MATE2-K
HGNC, UniProt SLC47A1, Q96FL8 SLC47A2, Q86VL8
Substrates quinidine [467], cephradine [467], metformin (Km 7.810 4M)
[467], cephalexin [467], cimetidine (Km 1.710
 4M) [369, 467],
paraquat [85]
guanidine [467], procainamide [334], metformin (Km 1.910 3M)
[334, 467], aciclovir [467], MPP+ [334], cimetidine (Km
1.210 4M) [334, 467], N1-methylnicotinamide [334]
Endogenous substrates thiamine [467], creatine [467] creatine [467], thiamine [467]
(Sub)family-selective inhibitors pyrimethamine (pKi 7.1) [249], cimetidine (pKi 6) [482] pyrimethamine (pKi 6.3) [249] – Mouse, cimetidine (pKi 5.1) [482]
Labelled ligands [14C]TEA [374, 469], [14C]metformin [467, 469] [14C]TEA [467]
Comments: DAPI has been used to allow quantification of MATE1 and MATE2-mediated transport activity [531]. MATE2 and MATE2-B are inactive splice variants of MATE2-K [334].
Further Reading
Damme K et al. (2011) Mammalian MATE (SLC47A) transport proteins: impact on efflux of
endogenous substrates and xenobiotics. Drug Metab. Rev. 43: 499-523 [PMID:21923552]
Motohashi H et al. (2013) Multidrug and toxin extrusion family SLC47: physiological,
pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol. Aspects Med. 34:
661-8 [PMID:23506899]
Terada T et al. (2008) Physiological and pharmacokinetic roles of H+/organic cation antiporters
(MATE/SLC47A). Biochem. Pharmacol. 75: 1689-96 [PMID:18262170]
Yonezawa A et al. (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to
pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br. J.
Pharmacol. 164: 1817-25 [PMID:21457222]
SLC48 heme transporter
Transporters! SLC superfamily of solute carriers! SLC48 heme transporter
Overview: HRG1 has been identified as a cell surface and lysosomal heme transporter [398]. In addition, evidence suggests this 4TM-containing protein associates with the V-ATPase in lysosomes [367].
Recent studies confirm its lysosomal location and demonstrate that it has an important physiological function in macrophages ingesting senescent red blood cells (erythrophagocytosis), recycling heme
(released from the red cell hemoglobin) from the phagolysosome into the cytosol, where the heme is subsequently catabolized to recycle the iron [511].
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Nomenclature Heme transporter
Systematic nomenclature SLC48A1
Common abreviation HRG1
HGNC, UniProt SLC48A1, Q6P1K1
Further Reading
Khan AA et al. (2013) Heme and FLVCR-related transporter families SLC48 and SLC49. Mol. Aspects Med. 34: 669-82 [PMID:23506900]
SLC49 family of FLVCR-related heme transporters
Transporters! SLC superfamily of solute carriers! SLC49 family of FLVCR-related heme transporters
Overview: FLVCR1 was initially identified as a cell-surface
attachment site for feline leukemia virus subgroup C [464], and
later identified as a cell surface accumulation which exports
heme from the cytosol [395]. A recent study indicates that an
isoform of FLVCR1 is located in the mitochondria, the site of the
final steps of heme synthesis, and appears to transport heme into
the cytosol [89]. FLVCR-mediated heme transport is essential for
erythropoiesis. Flvcr1 gene mutations have been identified as the
cause of PCARP
(posterior column ataxia with retinitis pigmentosa (PCARP)
[397].There are three paralogs of FLVCR1 in the human genome.
FLVCR2, most similar to FLVCR1 [319], has been reported to
function as a heme importer [129]. In addition, a congenital
syndrome of proliferative vasculopathy and hydranencephaly,
also known as Fowler’s syndrome, is associated with a
loss-of-function mutation in FLVCR2 [340].
The functions of the other two members of the SLC49 family,
MFSD7 and DIRC2, are unknown, although DIRC2 has been
implicated in hereditary renal carcinomas [46].
Nomenclature Feline leukemia virus subgroup C cellular receptor family, member 1 Feline leukemia virus subgroup C cellular receptor family, member 2
Systematic nomenclature SLC49A1 SLC49A2
Common abreviation FLVCR1 FLVCR2
HGNC, UniProt FLVCR1, Q9Y5Y0 FLVCR2, Q9UPI3
Substrates heme [395] heme [129]
Stoichiometry Unknown Unknown
Comments: Non-functional splice alternatives of FLVCR1 have been implicated as a cause of a congenital red cell aplasia, Diamond Blackfan anemia [405].
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Further Reading
Khan AA et al. (2013) Heme and FLVCR-related transporter families SLC48 and SLC49. Mol. Aspects
Med. 34: 669-82 [PMID:23506900]
Khan AA et al. (2011) Control of intracellular heme levels: heme transporters and heme
oxygenases. Biochim. Biophys. Acta 1813: 668-82 [PMID:21238504]
Krishnamurthy P et al. (2007) The role of transporters in cellular heme and porphyrin homeostasis.
Pharmacol. Ther. 114: 345-58 [PMID:17368550]
Latunde-Dada GO et al. (2006) Recent advances in mammalian haem transport. Trends Biochem.
Sci. 31: 182-8 [PMID:16487711]
SLC50 sugar transporter
Transporters! SLC superfamily of solute carriers! SLC50 sugar transporter
Overview: A mouse stromal cell cDNA library was used to clone C2.3 [463], later termed Rag1-activating protein 1, with a sequence homology predictive of a 4TM topology. The plant orthologues,
termed SWEETs, appear to be 7 TM proteins, with extracellular N-termini, and the capacity for bidirectional flux of D-glucose [82]. Expression of mouse SWEET in the mammary gland was suggestive of
a role in Golgi lactose synthesis [82].
Nomenclature SLC50 sugar exporter
Systematic nomenclature SLC50A1
Common abreviation RAG1AP1
HGNC, UniProt SLC50A1, Q9BRV3
Further Reading
Wright EM. (2013) Glucose transport families SLC5 and SLC50. Mol. Aspects Med. 34: 183-96
[PMID:23506865]
Wright EM et al. (2011) Biology of human sodium glucose transporters. Physiol. Rev. 91: 733-94
[PMID:21527736]
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SLC51 family of steroid-derived molecule transporters
Transporters! SLC superfamily of solute carriers! SLC51 family of steroid-derived molecule transporters
Overview: The SLC51 organic solute transporter family of
transporters is a pair of heterodimeric proteins which regulate
bile salt movements in the bile duct, small intestine and kidney,
and elsewhere, as part of the enterohepatic circulation [28, 109].
OSTα/OSTβ is also expressed in steroidogenic cells of the brain
and adrenal gland, where it may contribute to steroid movement
[154]. Bile acid transport is suggested to be facilitative and
independent of sodium, potassium, chloride ions or protons [28,
109]. OSTα/OSTβ heterodimers have been shown to transport
[3H]taurocholic acid, [3H]dehydroepiandrosterone sulphate,
[3H]estrone-3-sulphate, [3H]pregnenolone sulphate and
[3H]dehydroepiandrosterone sulphate [28, 109, 154]. OSTα is
suggested to be a seven TM protein, while OSTβ is a single TM
‘ancillary’ protein, both of which are thought to have
intracellular C-termini [315]. Bimolecular fluorescence
complementation studies suggest the possibility of OSTα
homo-oligomers, as well as OSTα/OSTβ hetero-oligomers [92,
315].
Nomenclature Organic solute transporter subunit α Organic solute transporter subunit β
Systematic nomenclature SLC51A1 SLC51A1BP
Common abreviation OSTα OSTβ
HGNC, UniProt SLC51A, Q86UW1 SLC51B, Q86UW2
Further Reading
Ballatori N. (2011) Pleiotropic functions of the organic solute transporter Ostα-Ostβ. Dig Dis 29:
13-7 [PMID:21691099]
Ballatori N et al. (2013) The heteromeric organic solute transporter, OSTα-OSTβ/SLC51: a
transporter for steroid-derived molecules. Mol. Aspects Med. 34: 683-92 [PMID:23506901]
Dawson PA. (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition.
Handb Exp Pharmacol 169-203 [PMID:21103970]
SLC52 family of riboflavin transporters
Transporters! SLC superfamily of solute carriers! SLC52 family of riboflavin transporters
Overview: riboflavin, also known as vitamin B2, is a precursor of the enzyme cofactors flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). Riboflavin transporters are predicted to
possess 10 or 11 TM segments.
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Nomenclature solute carrier family 52 solute carrier family 52 solute carrier family 52
(riboflavin transporter), member 1 (riboflavin transporter), member 2 (riboflavin transporter), member 3
Systematic nomenclature SLC52A1 SLC52A2 SLC52A3
Common abreviation RFVT1 RFVT2 RFVT3
HGNC, UniProt SLC52A1, Q9NWF4 SLC52A2, Q9HAB3 SLC52A3, Q9NQ40
Endogenous substrates riboflavin (Km 1.310
 3M) [530] riboflavin (Km 9.810
 4M) [530] riboflavin (Km 3.310
 4M) [530]
Stoichiometry Unknown Unknown H+-dependent
Comments: Although expressed elsewhere, RFVT3 is found on the luminal surface of intestinal epithelium and is thought to mediate uptake of dietary riboflavin, while RFVT1 and RFVT2 are thought
to allow movement from the epithelium into the blood.
Further Reading
Yamamoto S et al. (2009) Identification and functional characterization of rat riboflavin transporter
2. J. Biochem. 145: 437-43 [PMID:19122205]
Yonezawa A et al. (2013) Novel riboflavin transporter family RFVT/SLC52: identification,
nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Mol. Aspects
Med. 34: 693-701 [PMID:23506902]
SLCO family of organic anion transporting polypeptides
Transporters! SLC superfamily of solute carriers! SLCO family of organic anion transporting polypeptides
Overview: The SLCO superfamily is comprised of the organic
anion transporting polypeptides (OATPs). The 11 human OATPs
are divided into 6 families and ten subfamilies based on amino
acid identity. These proteins are located on the plasma
membrane of cells throughout the body. They have 12 TM
domains and intracellular termini, with multiple putative
glycosylation sites. OATPs mediate the sodium-independent
uptake of a wide range of amphiphilic substrates, including
many drugs and toxins. Due to the multispecificity of these
proteins, this guide lists classes of substrates and inhibitors for
each family member. More comprehensive lists of substrates,
inhibitors, and their relative affinities may be found in the
review articles listed below.
Nomenclature OATP1A2 OATP1B1 OATP1B3 OATP1C1
Systematic nomenclature SLCO1A2 SLCO1B1 SLCO1B3 SLCO1C1
HGNC, UniProt SLCO1A2, P46721 SLCO1B1, Q9Y6L6 SLCO1B3, Q9NPD5 SLCO1C1, Q9NYB5
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(continued)
Nomenclature OATP1A2 OATP1B1 OATP1B3 OATP1C1
Substrates fluoroquinolones, beta blockers,
deltorphin II, rosuvastatin,
fexofenadine, bromsulphthalein,
anticancer drugs, antibiotics, HIV
protease inhibitors, talinolol,
ouabain, microcystin
statins, opioids, β-lactam
antibiotics, bile acid derivatives
and conjugates,
bromsulphthalein, anticancer
drugs, HIV protease inhibitors,
fexofenadine, antifungals, ACE
inhibitors, rifampicin, endothelin
receptor antagonists, sartans
rifampicin, opioids, sartans,
statins, digoxin, anticancer
drugs, bromsulphthalein, bile
acid derivatives and conjugates,
β-lactam antibiotics, ouabain,
amanitin, saquinavir,
fexofenadine, erythromycin-A,
phalloidin
statins, bromsulphthalein
Endogenous substrates bile acids, thyroid hormones,
steroid conjugates, bilirubin,
PGE2
leukotrienes, steroid conjugates,
thyroid hormones, bile acids,
bilirubin
steroid conjugates, thyroid
hormones, bile acids, CCK-8
(CCK, P06307), bilirubin, LTC4
thyroid hormones, steroid
conjugates
Ligands – pravastatin (Binding) – –
Inhibitors naringin [25], rifampicin,
rifamycin SV
cyclosporin A, gemfibrozil [364],
glycyrrhizin, indocyanine green,
rifampicin, rifamycin SV,
sildenafil
cyclosporin A (pIC50 6.1) [478],
sildenafil (pIC50 6.1) [478],
rifampicin (pIC50 5.8) [478],
gemfibrozil, glycyrrhizin,
rifamycin SV
DPDPE, probenecid,
taurocholic acid
Labelled ligands [3H]BSP, [3H]DPDPE,
[3H]estrone-3-sulphate
[3H]estradiol-17β-glucuronide,
[3H]estrone-3-sulphate
[3H]BSP,
[3H]CCK-8 (human, mouse, rat),
[3H]estradiol-17β-glucuronide
[125I]thyroxine, [3H]BSP,
[3H]estrone-3-sulphate
Comments Although rat and mouse
OATP1A4 are considered the
orthologs of human OATP1A2
we do not cross-link to gene or
protein databases for these since
in reality there are five genes in
rodents that arose through gene
duplication in this family and it is
not clear which one of these is
the "true" ortholog.
Other inhibitors include, fibrates,
flavonoids, glitazones and
macrolide antibiotics. pravastatin
is used as a probe
Other inhibitors include, HIV
protease inhibitors, glitazones
and macrolide antibiotics
–
Nomenclature OATP2A1 OATP2B1 OATP3A1 OATP4A1 OATP4C1
Systematic
nomenclature
SLCO2A1 SLCO2B1 SLCO3A1 SLCO4A1 SLCO4C1
HGNC, UniProt SLCO2A1, Q92959 SLCO2B1, O94956 SLCO3A1, Q9UIG8 SLCO4A1, Q96BD0 SLCO4C1, Q6ZQN7
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(continued)
Nomenclature OATP2A1 OATP2B1 OATP3A1 OATP4A1 OATP4C1
Substrates synthetic prostaglandin
derivatives
amiodarone,
bromsulphthalein, statins,
glibenclamide, aliskiren,
fexofenadine, talinolol,
bosentan, telmisartan
– penicillin G dipeptidyl peptidase-4
inhibitors, anticancer
drugs, cardiac
glycosides
Endogenous substrates prostaglandins, eicosanoids estrone-3-sulphate,
dehydroepiandrosterone sulphate,
T4
BQ123, vasopressin
(AVP, P01185), thyroid
hormones,
prostaglandins
thyroid hormones,
prostaglandins, bile
acids, steroid
conjugates
thyroid hormones,
cyclic AMP, steroid
conjugates
Inhibitors bromocresol green
(Inhibition of PGF2α uptake
in PGT-expressing HeLa cells)
(pKi 5.4) [263] – Rat,
bromsulphthalein (Inhibition
of PGF2α uptake in
PGT-expressing HeLa cells)
(pKi 5.2) [263] – Rat
gemfibrozil, glibenclamide,
rifamycin SV
– – –
Labelled ligands [3H]PGE2 (Binding) [78] [
3H]BSP,
[3H]estrone-3-sulphate
[3H]PGE2,
[3H]estrone-3-sulphate [
3H]estrone-3-sulphate
[3H]digoxin
Comments Other inhibitors include
NSAIDs
Other inhibitors include
glitazones and citrus juices
– – –
Further Reading
Gong IY et al. (2013) Impact of genetic variation in OATP transporters to drug disposition and
response. Drug Metab. Pharmacokinet. 28: 4-18 [PMID:23047721]
Hagenbuch B et al. (2013) The SLCO (former SLC21) superfamily of transporters. Mol. Aspects Med.
34: 396-412 [PMID:23506880]
König J et al. (2013) Transporters and drug-drug interactions: important determinants of drug
disposition and effects. Pharmacol. Rev. 65: 944-66 [PMID:23686349]
Obaidat A et al. (2012) The expression and function of organic anion transporting polypeptides in
normal tissues and in cancer. Annu. Rev. Pharmacol. Toxicol. 52: 135-51 [PMID:21854228]
Roth M et al. (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the
SLCO and SLC22A gene superfamilies. Br. J. Pharmacol. 165: 1260-87 [PMID:22013971]
Shitara Y et al. (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in
drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug
Dispos 34: 45-78 [PMID:23115084]
Stieger B et al. (2014) Organic anion-transporting polypeptides. Curr Top Membr 73: 205-32
[PMID:24745984]
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Patched family
Other protein targets! Patched family
Overview: NPC1L1 acts in the gut epithelium to allow the accumulation of dietary cholesterol through a clathrin-dependent mechanism. Ezetimibe is used to reduce cholesterol absorption through
inhibition of NPC1L1.
Nomenclature NPC1-like 1
HGNC, UniProt NPC1L1, Q9UHC9
Selective antagonists ezetimibe (Inhibition) (pKd 6.7) [21]
Searchable database: http://www.guidetopharmacology.org/index.jsp Patched family 6199
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